sotalol has been researched along with Atrial Fibrillation in 324 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Sotalol is a nonselective β-adrenergic receptor antagonist with class III antiarrhythmic properties that has been mostly used for atrial fibrillation treatment and suppressing recurrent ventricular tachyarrhythmias." | 9.41 | The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review. ( Alvarez, C; Augustin, N; Kluger, J, 2023) |
| "Sotalol is recommended to prevent relapse of atrial fibrillation after cardioversion (CV)." | 9.22 | Reduction over time of QTc prolongation in patients with sotalol after cardioversion of atrial fibrillation. ( Darpö, B; Ferber, G; Frick, M; Lenhoff, H; Rosenqvist, M, 2016) |
| "Sotalol is a commonly prescribed antiarrhythmic drug (AAD) used for maintaining sinus rhythm in patients with atrial fibrillation (AF)." | 9.19 | Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. ( Al-Khatib, SM; Allen-LaPointe, N; Anstrom, KJ; Daubert, JP; DeWald, T; Horton, JR; Lokhnygina, Y; Peterson, ED; Piccini, JP; Shaw, LK; Steinberg, BA; Thomas, K; Wojdyla, DM, 2014) |
| " The aim of our study was to compare sotalol (S) versus beta-blocking agents (BB) in terms of prevention of ATA, cardioversions (CVs), and cardiovascular hospitalizations (H) in patients paced for bradycardia-tachycardia form of sinus node disease (BT-SND)." | 9.13 | The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker. ( Boriani, G; Botto, G; Capucci, A; Favale, S; Marotta, T; Molon, G; Porfilio, A; Proclemer, A; Spampinato, A; Vimercati, M, 2008) |
| "To evaluate the effects and adverse reactions of amiodarone and sotalol in treatment of atrial fibrillation." | 9.12 | [Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study]. ( Chen, YX; Guo, WL; Huang, CX; Jiang, H; Jin, CR; Liu, ZM; Niu, F; Yang, B, 2006) |
| "To evaluate the efficacy of azimilide, a new class III anti-arrhythmic drug, we studied 658 patients with symptomatic persistent atrial fibrillation, adequate anticoagulant therapy, and planned electrical cardioversion." | 9.12 | Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. ( Borggrefe, M; Lombardi, F; Lüderitz, B; Ruzyllo, W, 2006) |
| "This is a substudy of a prospective randomized controlled trial (SAFE-Trial) in which amiodarone, sotalol, and placebo for persistent atrial fibrillation were evaluated." | 9.12 | Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. ( Batcher, EL; Hershman, JM; Reda, DJ; Singh, BN; Singh, SN; Tang, XC, 2007) |
| "Patients (n=187) with symptomatic persistent atrial fibrillation at the background of ischemic heart disease after restoration of sinus rhythm were randomized for treatment with sotalol 80 - 160 mg/day (n=48), or with combinations of sotalol with perindopril 4 - 8 mg/day (n=48), rosuvastatin 5 - 20 mg/day (n=45), or omega-3 polyunsaturated fatty acids containing preparation 1 g/day (n=45)." | 9.12 | [Influence of perindopril, rosuvastatin, or omega-3 polyunsaturated fatty acids on efficacy of antirecurrence therapy with sotalol in patients with persistent atrial fibrillation]. ( Bodrikova, VV; Kanorskaia, IuS; Kanorskiĭ, SG, 2007) |
| "Amiodarone and sotalol are commonly used for the maintenance of sinus rhythm, but the efficacy of these agents administered as high-dose infusions for rapid conversion of atrial fibrillation is unknown." | 9.11 | Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. ( Cooper, MJ; Crampton, R; Eipper, V; Guy, D; Kijvanit, P; Ross, DL; Thomas, SP; Wallace, E, 2004) |
| "Oral low-dose sotalol provides a considerable reduction in the occurrence of atrial fibrillation." | 9.11 | Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery. ( Blasco, M; Carbonell, N; Jordá, A; Martínez-León, J; Núñez, J; Otero, E; Sanjuán, R, 2004) |
| "These results show that MgCl(2), in addition to sotalol, is not more effective than sotalol alone in the prevention of tachyarrhythmias after CABG." | 9.11 | Magnesium in addition to sotalol does not influence the incidence of postoperative atrial tachyarrhythmias after coronary artery bypass surgery. ( Beukema, WP; Geertman, H; Sie, HT; van der Starre, PJ; van Rooyen-Butijn, M, 2004) |
| " We investigated the effects of pretreatment with oral d,l-sotalol on rate-dependent changes in atrial monophasic action potential (MAP) duration after cardioversion of chronic AF with reference to the efficacy in preventing the arrhythmia recurrence." | 9.11 | Sotalol reverses remodeled action potential in patients with chronic atrial fibrillation but does not prevent arrhythmia recurrence. ( Ito, A; Kodama, I; Osaka, T; Yamazaki, M; Yokoyama, E, 2004) |
| "This prospective, randomized, double-blind, placebo-controlled study compared the efficacy and safety of amiodarone and sotalol in the prevention of atrial fibrillation (AF) following open heart surgery." | 9.11 | Amiodarone versus sotalol for the treatment of atrial fibrillation after open heart surgery: the Reduction in Postoperative Cardiovascular Arrhythmic Events (REDUCE) trial. ( Arcidi, JM; Hilleman, DE; Lenz, TL; Mohiuddin, SM; Mooss, AN; Packard, KA; Rovang, KS; Sugimoto, JT; Wurdeman, RL, 2004) |
| "This prospective, randomized, single-blinded, placebo-controlled study compared the efficacy and safety of sotalol and propafenone when used for long-term prevention of atrial fibrillation." | 9.11 | Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. ( Chlouverakis, GI; Hamilos, ME; Igoumenidis, NE; Klapsinos, NC; Kochiadakis, GE; Tzerakis, PG; Vardas, PE, 2004) |
| "Flecainide and sotalol prolong the atrial action potential during atrial fibrillation in humans." | 9.11 | Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation. ( Breithardt, G; Eckardt, L; Engelen, M; Franz, MR; Haverkamp, W; Kirchhof, P; Ribbing, M; Wasmer, K, 2005) |
| "In this double-blind, placebo-controlled trial, we randomly assigned 665 patients who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (267 patients), sotalol (261 patients), or placebo (137 patients) and monitored them for 1 to 4." | 9.11 | Amiodarone versus sotalol for atrial fibrillation. ( Atwood, JE; Ezekowitz, MD; Fletcher, RD; Harris, CL; Jacobson, AK; Lewis, HD; Lopez, B; Raisch, DW; Reda, DJ; Sharma, SC; Singh, BN; Singh, SN; Tang, XC, 2005) |
| "The Sotalol-Amiodarone Fibrillation Efficacy Trial (SAFE-T) is a randomized, double-blind, multicenter, placebo-controlled trial in which the effects of sotalol and amiodarone in maintaining stability of sinus rhythm are being examined in patients with persistent atrial fibrillation at 20 Veterans Affairs medical centers." | 9.10 | Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). ( Antman, EM; Atwood, JE; Ezekowitz, MD; Falk, RH; Fletcher, RD; Fye, CL; Jacobson, AK; Lewis, HD; Lopez, B; Reda, DJ; Sharma, SC; Singh, BN; Singh, SN; Tang, XC, 2003) |
| "For patients in whom antiarrhythmic drug therapy is indicated, low dose amiodarone significantly reduces atrial fibrillation-related costs by reducing the number of atrial fibrillation-related procedures." | 9.10 | Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. ( Couturier, A; Dubuc, M; Frasure-Smith, N; Gagné, P; Lambert, J; Lumer, GB; Nattel, S; Roy, D; Talajic, M; Thibault, B, 2002) |
| "To compare sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation." | 9.09 | An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. ( Birchall, AS; Channer, KS; Smith, M; Steeds, RP, 1999) |
| "The purpose of this prospective, randomized, double-blind, placebo-controlled study was to assess the efficacy of preoperatively and postoperatively administered oral d,l sotalol in preventing the occurrence of postoperative atrial fibrillation (AF)." | 9.09 | Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. ( Chao, S; Ergin, A; Gomes, JA; Ip, J; Lansman, S; Mehta, D; Newhouse, TT; Pe, E; Santoni-Rugiu, F, 1999) |
| "Currently d,l-sotalol is widely used to prevent recurrence of atrial fibrillation and/or atrial flutter, although a randomized dose-response study has not previously been conducted to guide therapy for this indication." | 9.09 | Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. ( Benditt, DG; Browne, K; Chang-Sing, P; Deering, TF; Jin, J; Singh, BN; Williams, JH; Zucker, R, 1999) |
| "To compare the efficacy and safety of sotalol and quinidine after conversion of atrial fibrillation (AF) of <6 months, a prospective multicenter trial enrolled 121 patients who were randomized to receive dl-sotalol (160 to 320 mg/day, 58 patients) or quinidine sulfate (600 to 800 mg/day, 63 patients)." | 9.09 | Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of São Paulo. ( de Paola, AA; Veloso, HH, 1999) |
| "We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone." | 9.09 | Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. ( Connolly, S; Dorian, P; Dubuc, M; Eisenberg, MJ; Gagné, P; Green, M; Kus, T; Lambert, J; Nattel, S; Roy, D; Talajic, M; Thibault, B, 2000) |
| "A prospective, randomized controlled trial of new-onset atrial fibrillation was conducted to compare the efficacy and safety of sotalol and amiodarone (active treatment) with rate control by digoxin alone for successful reversion to sinus rhythm at 48 hours." | 9.09 | A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. ( Joseph, AP; Ward, MR, 2000) |
| "In patients with persistent atrial fibrillation, oral treatment with magnesium alone or as an adjuvant to sotalol, does not influence the recurrence rate of atrial fibrillation after elective cardioversion." | 9.09 | The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. ( Darpö, B; Frick, M; Ostergren, J; Rosenqvist, M, 2000) |
| "To assess and compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation." | 9.09 | Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. ( Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Simantirakis, EN; Vardas, PE, 2000) |
| "This randomized study compared the efficacy and safety of amiodarone, propafenone and sotalol in the prevention of atrial fibrillation." | 9.09 | Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? ( Chrysostomakis, SI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Mavrakis, HE; Vardas, PE, 2000) |
| "To compare the effects of sotalol and metoprolol on heart rate, during isotonic (ITE) and isometric (IME) exercise and daily activities, in digitalized patients with chronic atrial fibrillation." | 9.09 | Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study. ( Igoumenidis, NE; Kalebubas, MD; Kanoupakis, EM; Kochiadakis, GE; Mavrakis, HE; Vardakis, KE; Vardas, PE, 2001) |
| "The purpose of the study was to compare the efficacy and safety of sotalol and bisoprolol in the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation." | 9.09 | Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. ( Alt, EU; Lehmann, G; Ndrepepa, G; Plewan, A; Schmitt, C; Schömig, A; Schreieck, J, 2001) |
| "This study was performed to evaluate, using a randomized double-blind, placebo-controlled protocol, the long-term efficacy and safety of propafenone and sotalol in maintaining sinus rhythm after conversion of recurrent symptomatic atrial fibrillation (AF)." | 9.09 | Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. ( Bellandi, F; Dabizzi, RP; Frascarelli, F; Giovannini, T; Leoncini, M; Maioli, M; Simonetti, I, 2001) |
| "We assessed the efficacy of postoperatively administered oral Sotalol in preventing the occurrence of postoperative atrial fibrillation." | 9.09 | Effect of Sotalol in the prevention of atrial fibrillation following coronary artery bypass grafting. ( Ishida, K; Matsuura, K; Sudo, Y; Takahara, Y, 2001) |
| "This study compared the efficacy and safety of sotalol and quinidine for conversion and prevention of recurrent atrial fibrillation." | 9.08 | Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. ( Baedeker, F; Hohnloser, SH; van de Loo, A, 1995) |
| "Aim of the present study was to assess the efficacy and safety of flecainide (F) and sotalol (S) for the prevention of recurrences of paroxysmal atrial fibrillation (PAF)." | 9.08 | [A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation]. ( Burattini, M; Carunchio, A; Ceci, V; Fera, MS; Galati, A; Greco, G; Mazza, A, 1995) |
| "We randomized 61 patients with paroxysmal atrial fibrillation (AF) ( < 48 hours from onset) to either sotalol or quinidine treatment." | 9.08 | Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). ( Halinen, MO; Huttunen, M; Paakkinen, S; Tarssanen, L, 1995) |
| "To assess the propafenone and sotalol efficacy in the prevention of paroxysmal atrial fibrillation (FA) we enrolled, in a double blind placebo controlled study over 1 year, 300 patients (168 males); mean age 52." | 9.08 | [Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study]. ( Bellandi, F; Cantini, F; Dabizzi, RP; Niccoli, L; Palchetti, R, 1996) |
| "The main goal of this study is to evaluate the safety and efficacy of propafenone versus sotalol as an initial choice of treatment in patients with symptomatic paroxysmal atrial fibrillation (AF), according to a double-blind randomized system." | 9.08 | Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. ( Chang, MS; Chen, SA; Chen, YJ; Cheng, JJ; Chiang, CE; Fong, AN; Huang, JL; Lee, SH; Tai, CT; Wen, ZC; Yu, WC, 1997) |
| "Sotalol's usefulness in treatment of atrial fibrillation and atrial flutter is unproven." | 9.08 | Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. ( Ferrick, KJ; Fisher, JD; Gallik, DM; Kim, SG; Roth, JA, 1997) |
| "To compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation (AF), 70 patients were entered into a randomized, double-blind study." | 9.08 | Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. ( Igoumenidis, NE; Kanoupakis, EM; Kochiadakis, GE; Marketou, ME; Solomou, MC; Vardas, PE, 1998) |
| "To analyze the recurrences of atrial fibrillation in patients treated with sotalol or quinidine." | 9.08 | [Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP]. ( de Paola, AA; Veloso, HH, 1998) |
| "This study sought to compare the efficacy and safety of intravenous flecainide and sotalol for immediate cardioversion of atrial fibrillation." | 9.08 | Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. ( Ebner, A; Gatterer, E; Gattermeier, M; Heinze, G; Hohenwallner, W; Kratzer, H; Kuhn, P; Lenz, K; Poelzl, G; Reisinger, J; Slany, J; Wiesinger, K; Zeindlhofer, E, 1998) |
| "Thus, a selective approach based on a clinical risk prediction algorithm should improve the cost-effectiveness and safety of low-dose sotalol in the prevention of atrial fibrillation after coronary bypass surgery." | 9.08 | Selective versus non-selective antiarrhythmic approach for prevention of atrial fibrillation after coronary surgery: is there a need for pre-operative risk stratification? A prospective placebo-controlled study using low-dose sotalol. ( Buser, P; Huber, M; Osswald, S; Pfisterer, M; Schmidhauser, C; Skarvan, K; Stulz, P; Weber, UK, 1998) |
| "The purpose of our study (conducted between August 1995 and September 1996) was to evaluate prospectively the efficacy of intravenous administration (in 10 min) of sotalol, flecainide or the combination of these drugs to restore sinus rhythm in patients (without cardiac/pulmonary failure) who came to the First Heart Aid of our hospital with atrial fibrillation lasting less than 24 h." | 9.08 | Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide. ( Braat, SH; Heymeriks, J; Peters, FP; Wellens, HJ, 1998) |
| "To compare the efficacy and safety of a single dose of ibutilide, a new class III antiarrhythmic drug, with that of DL-sotalol in terminating chronic atrial fibrillation or flutter in haemodynamically stable patients." | 9.08 | Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. ( Golitsyn, SR; Harry, JD; Perry, KT; Ruda, MY; Stangl, K; Steinbeck, G; Touboul, P; Van Wijk, LV; Vos, MA; Wellens, HJ, 1998) |
| "To establish the value of adjuvant dl-sotalol to digoxin for control of the ventricular response in chronic atrial fibrillation, 60 patients were evaluated in a multicenter, randomized, double-blind, parallel, placebo-controlled study." | 9.07 | Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group. ( Bellinger, R; Brodsky, M; Powers, L; Saini, R; Weiss, R; Zoble, R, 1994) |
| "This study investigated the hemodynamic effects of oral sotalol during both sinus rhythm and paroxysmal atrial fibrillation." | 9.07 | Hemodynamic effects of oral sotalol during both sinus rhythm and atrial fibrillation. ( Alboni, P; Chioin, R; Fucà, G; Paparella, N; Pedini, I; Razzolini, R; Scarfò, S, 1993) |
| "This open, parallel-group study compares quinidine and sotalol treatment for maintenance of sinus rhythm after direct current conversion of patients with chronic atrial fibrillation." | 9.06 | Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. ( Edvardsson, N; Juul-Möller, S; Rehnqvist-Ahlberg, N, 1990) |
| "The efficacy of sotalol in treating acute atrial fibrillation and flutter after open heart surgery was compared with that of a digoxin/disopyramide combination." | 9.05 | Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. ( Campbell, TJ; Gavaghan, TP; Morgan, JJ, 1985) |
| "To assess the clinical and cost-effectiveness of magnesium sulphate compared with sotalol, and to assess the clinical effectiveness of magnesium sulphate compared with placebo in the prevention of atrial fibrillation (AF) in patients who have had a coronary artery bypass graft (CABG)." | 8.84 | Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. ( Frampton, GK; Jones, J; Price, A; Shepherd, J; Tanajewski, L; Turner, D, 2008) |
| "Many clinicians choose sotalol for the prevention of recurrences of atrial fibrillation (AF) as an alternative to quinidine, which has been associated with an increase in long-term mortality." | 8.80 | Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation. ( Bauman, J; Southworth, MR; Viana, M; Zarembski, D, 1999) |
| "The DASH-AF (Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation) trial evaluates the safety and feasibility of intravenous (IV) sotalol, achieving a steady state with maximum QTc prolongation within 6 hours instead of the traditional 5-dose inpatient oral (PO) titration." | 8.31 | Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With Atrial Fibrillation (DASH-AF). ( Ahmed, A; Atkins, D; Bawa, D; Bommana, S; Bush, J; Charate, R; Darden, D; Garg, J; Gopinathannair, R; Kabra, R; Kennedy, R; Koreber, S; Lakkireddy, D; Mohanty, S; Natale, A; Park, P; Pothineni, NVK; Seo, BW; Tummala, R; Vasamreddy, C, 2023) |
| "Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk for bleeding." | 8.31 | Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. ( Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E, 2023) |
| "Sotalol and dronedarone are both used for maintenance of sinus rhythm for patients with atrial fibrillation." | 8.31 | Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fibrillation. ( Blomström-Lundqvist, C; Camm, AJ; Din, N; Fan, J; Kabadi, S; Kowey, P; Pundi, K; Rashkin, J; Sandhu, AT; Singh, JP; Turakhia, MP; Wieloch, M, 2023) |
| "Use of d,l-sotalol for rhythm control in patients with atrial fibrillation (AF) has raised safety concerns." | 8.31 | Mortality and ventricular arrhythmias in patients on d,l-sotalol for rhythm control of atrial fibrillation: A nationwide cohort study. ( Darpo, B; Frick, M; Järnbert-Petersson, H; Lenhoff, H; Tornvall, P, 2023) |
| "There exists variability in the administration of in-patient sotalol therapy for symptomatic atrial fibrillation (AF)." | 8.12 | Economics and outcomes of sotalol in-patient dosing approaches in patients with atrial fibrillation. ( B Muhlestein, J; Burnham, TS; Jared Bunch, T; L Anderson, J; L Bair, T; Steinberg, BA; T May, H; U Knowlton, K; Varela, DL, 2022) |
| "We aimed to evaluate the effectiveness and safety of dronedarone versus sotalol in real-world practice in Asian patients with atrial fibrillation (AF)." | 7.96 | Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study. ( Choi, EK; Kim, JA; Kim, JH; Kwon, TY; Lee, SR; Lee, YE; Oh, S, 2020) |
| "To evaluate the effect of sotalol on heart rate (HR), QT interval, atrial fibrillatory rate, and success of cardioversion in horses with naturally occurring chronic atrial fibrillation (AF)." | 7.88 | Effect of sotalol on heart rate, QT interval, and atrial fibrillation cycle length in horses with atrial fibrillation. ( Broux, B; De Clercq, D; Decloedt, A; Deprez, P; van Loon, G; Van Steenkiste, G; Ven, S; Vera, L, 2018) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 7.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "To evaluate the efficacy of sotalol depending on the magnitude of changes in adrenal responsiveness and autonomic nervous system tone in patients with paroxysmal atrial fibrillation (AF)." | 7.83 | [A change in adrenal responsiveness in sotalol-treated patients with paroxysmal atrial fibrillation depending on autonomic nervous system tone]. ( Afanasyev, SA; Batalov, RE; Borisova, EV; Kisteneva, IV; Popov, SV; Rebrova, TY, 2016) |
| "Sotalol and amiodarone are commonly prescribed antiarrhythmics for the treatment of post-operative atrial fibrillation (POAF)." | 7.83 | Mortality risk of sotalol and amiodarone for post-CABG atrial fibrillation. ( Brophy, JM; Johnson, SM, 2016) |
| "To estimate cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation (AF)." | 7.81 | Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia. ( Jankovic, SM; Kostic, M; Paunovic, D; Tesic, D, 2015) |
| "Inpatient antiarrhythmic drug initiation for atrial fibrillation is mandated for dofetilide (DF) and is often performed for sotalol (SL), particularly if proarrhythmia risk factors are present." | 7.81 | Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation. ( Agusala, K; Caprio, T; Kulkarni, C; Oesterle, A; Passman, R; Subacius, H, 2015) |
| "Ranolazine is evaluated for antiarrhythmic therapy of atrial fibrillation (AF)." | 7.79 | Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation. ( Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T, 2013) |
| "In several clinical and pre-clinical studies, application of ranolazine (RAN) led to suppression of atrial fibrillation (AF)." | 7.79 | Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness. ( Belardinelli, L; Breithardt, G; Eckardt, L; Frommeyer, G; Ghezelbash, S; Milberg, P; Osada, N; Rajamani, S; Razvan, R, 2013) |
| " The aim of this study was to determine the effects of IPC versus intravenous (IV) d,l-sotalol and flecainide infusion on transmural atrial electrophysiology and sustained atrial fibrillation (AF) in the goat." | 7.75 | Effects of intrapericardial sotalol and flecainide on transmural atrial electrophysiology and atrial fibrillation. ( Accord, RE; Allessie, MA; Hermans, JJ; Maessen, JG; Schotten, U; Smits, JF; van Brakel, TJ, 2009) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 7.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "This study evaluated antiarrhythmic effects of d,l-sotalol in a canine atrial fibrillation (AF) model with left ventricular dysfunction." | 7.75 | d,l-Sotalol reverses abbreviated atrial refractoriness and prevents promotion of atrial fibrillation in a canine model with left ventricular dysfunction induced by atrial tachypacing. ( Fujiki, A; Hashimoto, N; Inoue, H; Mizumaki, K; Nakatani, Y; Sakabe, M; Sakamoto, T, 2009) |
| "Sotalol is a class III antiarrhythmic agent that is highly effective for tachyarrhythmias in adults, but its efficacy in patients with congenital heart disease (CHD) remains unclear." | 7.74 | Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease. ( Kamakura, S; Kurosaki, K; Miyazaki, A; Ohuchi, H; Yagihara, T; Yamada, O, 2008) |
| " Antiarrhythmic therapy with sotalol at 240 mg/day was started, and after 48 h the patient experienced several episodes of sustained torsade de pointes, dramatic marked QT interval prolongation and negative T wave, in absence of overt cardiac disease, renal failure, electrolyte abnormalities or baseline QT interval prolongation." | 7.73 | Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease. ( Boldini, A; Brentana, L; D'Aloia, A; Dei Cas, L; Faggiano, P; Pedrinazzi, C; Procopio, R, 2005) |
| "The combination of sotalol and magnesium can significantly reduce the incidence of post-operative atrial fibrillation following coronary surgery." | 7.73 | Does prophylactic sotalol and magnesium decrease the incidence of atrial fibrillation following coronary artery bypass surgery: a propensity-matched analysis. ( Aerra, V; Fabri, BM; Grayson, AD; Kuduvalli, M; Moloto, AN; Oo, AY; Srinivasan, AK, 2006) |
| "We present 4 patients with atrial fibrillation treated with sotalol who developed torsade de pointes due to marked prolongation of the QT interval." | 7.72 | A case series of sotalol-induced torsade de pointes in patients with atrial fibrillation--a tale with a twist. ( Chua, T; Hsu, LF; Kam, RM; Tan, HH; Teo, WS, 2003) |
| "In experimental studies, sotalol has limited class III action in the electrically remodeled atrium and did not prevent atrial fibrillation (AF) induction." | 7.71 | Electrophysiologic actions of dl-sotalol in patients with persistent atrial fibrillation. ( Lau, CP; Tse, HF, 2002) |
| "We sought to determine the yield of in-hospital monitoring for detection of significant arrhythmia complications in patients starting sotalol therapy for atrial arrhythmias and to identify factors that might predict safe outpatient initiation." | 7.70 | Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. ( Chung, MK; Jaeger, FJ; Kidwell, GA; Miller, DP; Morant, VA; Niebauer, MJ; Pinski, SL; Schweikert, RA; Tchou, PJ; Trohman, RG; Wilkoff, BL, 1998) |
| " She had used sotalol 80 mg once daily for three years without any episodes of proarrhythmia or other adverse effects." | 7.70 | T wave alternans after sotalol: evidence for increased sensitivity to sotalol after conversion from atrial fibrillation to sinus rhythm. ( Tan, HL; Wilde, AA, 1998) |
| "To study the incidence and mode of onset of early reinitiation of atrial fibrillation (ERAF) following successful internal cardioversion of chronic atrial fibrillation, and to determine the effects of sotalol in the prevention of ERAF." | 7.70 | Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol. ( Ayers, GM; Lau, CP; Tse, HF, 1999) |
| "This study was designed to evaluate and compare the effects of oral sotalol for the treatment of vagal and adrenergic paroxysmal atrial fibrillation (PAF)." | 7.70 | Cardioversion with sotalol in selected patients with vagally and adrenergically mediated paroxysmal atrial fibrillation. ( Aslan, O; Bayata, S; Postaci, N; Yeşil, M; Yücel, O, 1999) |
| "This study was undertaken to assess the effects of sotalol on the transthoracic cardioversion energy requirement for chronic atrial fibrillation (AF) and on the atrial electrograms during AF recorded by two basket electrodes." | 7.70 | Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: assessment of the electrophysiological effects by biatrial basket electrodes. ( Huang, SK; Lai, LP; Lien, WP; Lin, JL; Tseng, YZ, 2000) |
| "To investigate the effects of low dose sotalol on the signal averaged surface P wave in patients with paroxysmal atrial fibrillation." | 7.69 | Effect of low dose sotalol on the signal averaged P wave in patients with paroxysmal atrial fibrillation. ( Cooper, J; de Bono, DP; Garratt, CJ; Stafford, PJ; Vincent, R, 1995) |
| "The aim of this study was to evaluate of oral sotalol hydrochloride effects on atrial signal-averaged ECG (ASAECG) during time- and frequency-domain analysis in patients with paroxysmal atrial fibrillation (PAF) during ischemic heart disease (IHD)." | 7.69 | [The effect of sotalol hydrochloride therapy on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. ( Banasiak, W; Fuglewicz, A; Kałka, D; Lacheta, W; Pieróg, M; Ponikowski, P; Telichowski, A; Telichowski, C; Wiech, K; Zeborowski, J, 1996) |
| "A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation." | 7.68 | Sotalol-induced torsade de pointes: management with magnesium infusion. ( Arstall, MA; Hii, JT; Horowitz, JD; Lehman, RG, 1992) |
| "Dronedarone was associated with a statistically significantly lower risk of all-cause death versus sotalol (hazard ratio [HR] = 0." | 7.01 | Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis. ( Blomström-Lundqvist, C; Camm, AJ; Crotty, C; Fazeli, MS; Kowey, PR; Kreidieh, B; Singh, JP; Turakhia, MP, 2023) |
| "Sotalol was initiated." | 6.73 | Bifocal versus unifocal right atrial pacing under plasma level controlled sotalol to prevent atrial fibrillation in patients with symptomatic sinus bradycardia and paroxysmal atrial fibrillation. ( Butter, C; Gerhardt, L; Helms, S; Schlegl, M; Stockburger, M, 2007) |
| "Sotalol is an antiarrhythmic agent with combined beta-blocking and class III antiarrhythmic properties." | 6.68 | Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. ( Das, G; Falk, R; Hanyok, JJ; Hardy, SA; Karagounis, L; Platia, E; Sung, RJ; Tan, HL, 1995) |
| " If sinus rhythm could not be established at that time, electric cardioversion was performed and the drug was continued in lower dosage thereafter." | 6.67 | [Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation--conversion and 12-month follow-up--a randomized comparison]. ( Betz, P; Kalusche, D; Roskamm, H; Stockinger, J, 1994) |
| "Sotalol is a beta-adrenergic blocking drug with the additional property of lengthening the cardiac action potential." | 6.67 | Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery. ( Dion, R; Evenepoel, M; Evrard, P; Goenen, M; Jacquet, L; Marenne, F; Verhelst, R, 1994) |
| "Sotalol was effective in reducing the incidence of atrial fibrillation." | 6.67 | Oral sotalol reduces the incidence of atrial fibrillation after coronary artery bypass surgery. ( Berggren, H; Edvardsson, N; Nyström, U; Pizzarelli, GP; Rådegran, K, 1993) |
| "Amiodarone was associated with the highest rate of patients experiencing at least one serious adverse event (OR 2." | 6.47 | Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. ( Eckert, L; Freemantle, N; Lafuente-Lafuente, C; Mitchell, S; Reynolds, M, 2011) |
| "Both amiodarone and sotalol were more effective than placebo treatment in reducing the incidence of postoperative AFF." | 6.41 | Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis. ( Lenz, TL; Mohiuddin, SM; Mooss, AN; Wurdeman, RL, 2002) |
| "This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC." | 5.72 | Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022) |
| " Sotalol is a nonselective β-adrenergic receptor antagonist with class III antiarrhythmic properties that has been mostly used for atrial fibrillation treatment and suppressing recurrent ventricular tachyarrhythmias." | 5.41 | The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review. ( Alvarez, C; Augustin, N; Kluger, J, 2023) |
| "In conclusion, for patients with paroxysmal atrial fibrillation admitted for dofetilide or sotalol loading, T-wave markers of increased repolarization heterogeneity are measurable within hours after initiation." | 5.40 | Electrocardiographic markers of repolarization heterogeneity during dofetilide or sotalol initiation for paroxysmal atrial fibrillation. ( Dorsey, P; Hayes, M; Kaplan, R; Passman, R; Sauer, AJ; Shah, SJ; Xue, J, 2014) |
| " Adverse events (AEs) associated with AADs may influence patient compliance and compromise the management of atrial fibrillation (AF)." | 5.37 | One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis. ( Jhaveri, M; Kim, MH; Klingman, D; Lin, J; Smith, PJ, 2011) |
| "Oral sotalol treatment was started after unsuccessful DC cardioversion and given at least 7 days before renewed cardioversion." | 5.33 | Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation. ( Frick, M; Nergärdh, A; Nordlander, R, 2006) |
| "If the fetal atrial flutter is resistant to these therapies, a combination of other congenital cardiac diseases or organic abnormalities should be considered." | 5.33 | Fetal atrial flutter: a case report and experience of sotalol treatment. ( Chiu, TH; Ho, M; Huang, LC; Hung, YC; Lee, CC; Wu, TH, 2006) |
| " Conversion to sinus rhythm was achieved in 16 out of 22 hemodynamically stable children with a dosage of 4." | 5.30 | Sotalol for atrial tachycardias after surgery for congenital heart disease. ( Beaufort-Krol, GC; Bink-Boelkens, MT, 1997) |
| "Univariate predictors for recurrence included coronary artery disease (p < 0." | 5.30 | Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol. ( Alt, E; Ammer, R; Ayers, GM; Lehmann, G; Pasquantonio, J; Pütter, K; Schömig, A, 1997) |
| "Sotalol is a betablocker with additional antiarrythmic properties." | 5.30 | [Sotalol--atrial fibrillation, reduced renal function and sudden death]. ( Bathen, J; Madsen, S, 1998) |
| "Sotalol has Class II and III antiarrhythmic effects." | 5.28 | Atrial fibrillation in Wolff-Parkinson-White syndrome: reversal of isoproterenol effects by sotalol. ( Madrid, AH; Maŕin Huerta, EM; Mestre, JL; Moro, C; Novo, L, 1992) |
| " Twenty-nine patients with supraventricular tachyarrhythmias were treated on 31 occasions to determine the effective therapeutic dosage and optimal method of administration." | 5.27 | Sotalol infusion in the treatment of supraventricular tachyarrhythmias. ( Harte, M; Horgan, JH; Teo, KK, 1985) |
| " The history of this approach has been disappointing, marked by catastrophic failures such as those of sodium channel blockers or sotalol to treat ventricular arrhythmias in the setting of structural cardiomyopathies, which led to increased mortality, and by modest clinical efficacy in paroxysmal atrial fibrillation." | 5.22 | The Future of Antiarrhythmic Drug Therapy: Will Drugs Be Entirely Replaced by Procedures? ( Valderrábano, M, 2022) |
| "Sotalol is recommended to prevent relapse of atrial fibrillation after cardioversion (CV)." | 5.22 | Reduction over time of QTc prolongation in patients with sotalol after cardioversion of atrial fibrillation. ( Darpö, B; Ferber, G; Frick, M; Lenhoff, H; Rosenqvist, M, 2016) |
| "Sotalol is a commonly prescribed antiarrhythmic drug (AAD) used for maintaining sinus rhythm in patients with atrial fibrillation (AF)." | 5.19 | Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. ( Al-Khatib, SM; Allen-LaPointe, N; Anstrom, KJ; Daubert, JP; DeWald, T; Horton, JR; Lokhnygina, Y; Peterson, ED; Piccini, JP; Shaw, LK; Steinberg, BA; Thomas, K; Wojdyla, DM, 2014) |
| " The aim of our study was to compare sotalol (S) versus beta-blocking agents (BB) in terms of prevention of ATA, cardioversions (CVs), and cardiovascular hospitalizations (H) in patients paced for bradycardia-tachycardia form of sinus node disease (BT-SND)." | 5.13 | The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker. ( Boriani, G; Botto, G; Capucci, A; Favale, S; Marotta, T; Molon, G; Porfilio, A; Proclemer, A; Spampinato, A; Vimercati, M, 2008) |
| "A total of 55 patients with AF and/or CHF (New York Heart Association functional class > or =III) who had ICDs were divided into 3 groups [amiodarone (n=24), sotalol (n=12), beta-blocker (n=19)] and the cumulative rates of inappropriate shocks were compared." | 5.13 | Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators. ( Choi, KJ; Kim, HY; Kim, J; Kim, YH; Lee, CH; Nam, GB; Park, HG; Park, KM, 2008) |
| "To evaluate the effects and adverse reactions of amiodarone and sotalol in treatment of atrial fibrillation." | 5.12 | [Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study]. ( Chen, YX; Guo, WL; Huang, CX; Jiang, H; Jin, CR; Liu, ZM; Niu, F; Yang, B, 2006) |
| "To evaluate the efficacy of azimilide, a new class III anti-arrhythmic drug, we studied 658 patients with symptomatic persistent atrial fibrillation, adequate anticoagulant therapy, and planned electrical cardioversion." | 5.12 | Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. ( Borggrefe, M; Lombardi, F; Lüderitz, B; Ruzyllo, W, 2006) |
| "This is a substudy of a prospective randomized controlled trial (SAFE-Trial) in which amiodarone, sotalol, and placebo for persistent atrial fibrillation were evaluated." | 5.12 | Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. ( Batcher, EL; Hershman, JM; Reda, DJ; Singh, BN; Singh, SN; Tang, XC, 2007) |
| "Patients (n=187) with symptomatic persistent atrial fibrillation at the background of ischemic heart disease after restoration of sinus rhythm were randomized for treatment with sotalol 80 - 160 mg/day (n=48), or with combinations of sotalol with perindopril 4 - 8 mg/day (n=48), rosuvastatin 5 - 20 mg/day (n=45), or omega-3 polyunsaturated fatty acids containing preparation 1 g/day (n=45)." | 5.12 | [Influence of perindopril, rosuvastatin, or omega-3 polyunsaturated fatty acids on efficacy of antirecurrence therapy with sotalol in patients with persistent atrial fibrillation]. ( Bodrikova, VV; Kanorskaia, IuS; Kanorskiĭ, SG, 2007) |
| "Amiodarone and sotalol are commonly used for the maintenance of sinus rhythm, but the efficacy of these agents administered as high-dose infusions for rapid conversion of atrial fibrillation is unknown." | 5.11 | Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. ( Cooper, MJ; Crampton, R; Eipper, V; Guy, D; Kijvanit, P; Ross, DL; Thomas, SP; Wallace, E, 2004) |
| "Oral low-dose sotalol provides a considerable reduction in the occurrence of atrial fibrillation." | 5.11 | Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery. ( Blasco, M; Carbonell, N; Jordá, A; Martínez-León, J; Núñez, J; Otero, E; Sanjuán, R, 2004) |
| "Atrial fibrillation (AF) frequently occurs after cardiac surgical procedures, and beta-blockers, sotalol, and amiodarone may reduce the frequency of AF after open heart surgery." | 5.11 | A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial. ( Auer, J; Berent, R; Eber, B; Hartl, P; Lamm, G; Lassnig, E; Lehner, E; Ng, CK; Puschmann, R; Schwarz, C; Strasser, U; Weber, T, 2004) |
| "These results show that MgCl(2), in addition to sotalol, is not more effective than sotalol alone in the prevention of tachyarrhythmias after CABG." | 5.11 | Magnesium in addition to sotalol does not influence the incidence of postoperative atrial tachyarrhythmias after coronary artery bypass surgery. ( Beukema, WP; Geertman, H; Sie, HT; van der Starre, PJ; van Rooyen-Butijn, M, 2004) |
| " We investigated the effects of pretreatment with oral d,l-sotalol on rate-dependent changes in atrial monophasic action potential (MAP) duration after cardioversion of chronic AF with reference to the efficacy in preventing the arrhythmia recurrence." | 5.11 | Sotalol reverses remodeled action potential in patients with chronic atrial fibrillation but does not prevent arrhythmia recurrence. ( Ito, A; Kodama, I; Osaka, T; Yamazaki, M; Yokoyama, E, 2004) |
| "This prospective, randomized, double-blind, placebo-controlled study compared the efficacy and safety of amiodarone and sotalol in the prevention of atrial fibrillation (AF) following open heart surgery." | 5.11 | Amiodarone versus sotalol for the treatment of atrial fibrillation after open heart surgery: the Reduction in Postoperative Cardiovascular Arrhythmic Events (REDUCE) trial. ( Arcidi, JM; Hilleman, DE; Lenz, TL; Mohiuddin, SM; Mooss, AN; Packard, KA; Rovang, KS; Sugimoto, JT; Wurdeman, RL, 2004) |
| "This prospective, randomized, single-blinded, placebo-controlled study compared the efficacy and safety of sotalol and propafenone when used for long-term prevention of atrial fibrillation." | 5.11 | Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. ( Chlouverakis, GI; Hamilos, ME; Igoumenidis, NE; Klapsinos, NC; Kochiadakis, GE; Tzerakis, PG; Vardas, PE, 2004) |
| "Flecainide and sotalol prolong the atrial action potential during atrial fibrillation in humans." | 5.11 | Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation. ( Breithardt, G; Eckardt, L; Engelen, M; Franz, MR; Haverkamp, W; Kirchhof, P; Ribbing, M; Wasmer, K, 2005) |
| "In this double-blind, placebo-controlled trial, we randomly assigned 665 patients who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (267 patients), sotalol (261 patients), or placebo (137 patients) and monitored them for 1 to 4." | 5.11 | Amiodarone versus sotalol for atrial fibrillation. ( Atwood, JE; Ezekowitz, MD; Fletcher, RD; Harris, CL; Jacobson, AK; Lewis, HD; Lopez, B; Raisch, DW; Reda, DJ; Sharma, SC; Singh, BN; Singh, SN; Tang, XC, 2005) |
| "There was a strong trend towards lower mortality associated with the use of class I antiarrhythmic agents or sotalol in managing patients with atrial fibrillation after acute myocardial infarction." | 5.10 | Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. ( Califf, RM; Criger, DA; Ohman, EM; Topol, EJ; White, HD; Wilcox, RG; Wong, CK, 2002) |
| "The Sotalol-Amiodarone Fibrillation Efficacy Trial (SAFE-T) is a randomized, double-blind, multicenter, placebo-controlled trial in which the effects of sotalol and amiodarone in maintaining stability of sinus rhythm are being examined in patients with persistent atrial fibrillation at 20 Veterans Affairs medical centers." | 5.10 | Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). ( Antman, EM; Atwood, JE; Ezekowitz, MD; Falk, RH; Fletcher, RD; Fye, CL; Jacobson, AK; Lewis, HD; Lopez, B; Reda, DJ; Sharma, SC; Singh, BN; Singh, SN; Tang, XC, 2003) |
| "In this multicentre randomized controlled trial, 68 patients affected by severely symptomatic paroxysmal atrial fibrillation were assigned, after successful atrioventricular junction ablation and pacing treatment, to antiarrhythmic drug therapy with amiodarone, propafenone, flecainide or sotalol and were compared with 69 patients assigned, after successful AV junction ablation and pacing treatment, to no antiarrhythmic drug therapy." | 5.10 | An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. ( Alboni, P; Bongiorni, MG; Botto, GL; Brignole, M; Bruna, C; Gasparini, M; Menozzi, C; Ometto, R; Verlato, R; Vincenti, A, 2002) |
| "For patients in whom antiarrhythmic drug therapy is indicated, low dose amiodarone significantly reduces atrial fibrillation-related costs by reducing the number of atrial fibrillation-related procedures." | 5.10 | Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. ( Couturier, A; Dubuc, M; Frasure-Smith, N; Gagné, P; Lambert, J; Lumer, GB; Nattel, S; Roy, D; Talajic, M; Thibault, B, 2002) |
| "To compare sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation." | 5.09 | An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. ( Birchall, AS; Channer, KS; Smith, M; Steeds, RP, 1999) |
| "The purpose of this prospective, randomized, double-blind, placebo-controlled study was to assess the efficacy of preoperatively and postoperatively administered oral d,l sotalol in preventing the occurrence of postoperative atrial fibrillation (AF)." | 5.09 | Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. ( Chao, S; Ergin, A; Gomes, JA; Ip, J; Lansman, S; Mehta, D; Newhouse, TT; Pe, E; Santoni-Rugiu, F, 1999) |
| "Currently d,l-sotalol is widely used to prevent recurrence of atrial fibrillation and/or atrial flutter, although a randomized dose-response study has not previously been conducted to guide therapy for this indication." | 5.09 | Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. ( Benditt, DG; Browne, K; Chang-Sing, P; Deering, TF; Jin, J; Singh, BN; Williams, JH; Zucker, R, 1999) |
| "To compare the efficacy and safety of sotalol and quinidine after conversion of atrial fibrillation (AF) of <6 months, a prospective multicenter trial enrolled 121 patients who were randomized to receive dl-sotalol (160 to 320 mg/day, 58 patients) or quinidine sulfate (600 to 800 mg/day, 63 patients)." | 5.09 | Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of São Paulo. ( de Paola, AA; Veloso, HH, 1999) |
| "We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone." | 5.09 | Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. ( Connolly, S; Dorian, P; Dubuc, M; Eisenberg, MJ; Gagné, P; Green, M; Kus, T; Lambert, J; Nattel, S; Roy, D; Talajic, M; Thibault, B, 2000) |
| "A prospective, randomized controlled trial of new-onset atrial fibrillation was conducted to compare the efficacy and safety of sotalol and amiodarone (active treatment) with rate control by digoxin alone for successful reversion to sinus rhythm at 48 hours." | 5.09 | A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. ( Joseph, AP; Ward, MR, 2000) |
| "In patients with persistent atrial fibrillation, oral treatment with magnesium alone or as an adjuvant to sotalol, does not influence the recurrence rate of atrial fibrillation after elective cardioversion." | 5.09 | The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. ( Darpö, B; Frick, M; Ostergren, J; Rosenqvist, M, 2000) |
| "To assess and compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation." | 5.09 | Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. ( Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Simantirakis, EN; Vardas, PE, 2000) |
| "This randomized study compared the efficacy and safety of amiodarone, propafenone and sotalol in the prevention of atrial fibrillation." | 5.09 | Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? ( Chrysostomakis, SI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Mavrakis, HE; Vardas, PE, 2000) |
| "To compare the effects of sotalol and metoprolol on heart rate, during isotonic (ITE) and isometric (IME) exercise and daily activities, in digitalized patients with chronic atrial fibrillation." | 5.09 | Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study. ( Igoumenidis, NE; Kalebubas, MD; Kanoupakis, EM; Kochiadakis, GE; Mavrakis, HE; Vardakis, KE; Vardas, PE, 2001) |
| "The purpose of the study was to compare the efficacy and safety of sotalol and bisoprolol in the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation." | 5.09 | Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. ( Alt, EU; Lehmann, G; Ndrepepa, G; Plewan, A; Schmitt, C; Schömig, A; Schreieck, J, 2001) |
| "This study was performed to evaluate, using a randomized double-blind, placebo-controlled protocol, the long-term efficacy and safety of propafenone and sotalol in maintaining sinus rhythm after conversion of recurrent symptomatic atrial fibrillation (AF)." | 5.09 | Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. ( Bellandi, F; Dabizzi, RP; Frascarelli, F; Giovannini, T; Leoncini, M; Maioli, M; Simonetti, I, 2001) |
| "We assessed the efficacy of postoperatively administered oral Sotalol in preventing the occurrence of postoperative atrial fibrillation." | 5.09 | Effect of Sotalol in the prevention of atrial fibrillation following coronary artery bypass grafting. ( Ishida, K; Matsuura, K; Sudo, Y; Takahara, Y, 2001) |
| "This study compared the efficacy and safety of sotalol and quinidine for conversion and prevention of recurrent atrial fibrillation." | 5.08 | Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. ( Baedeker, F; Hohnloser, SH; van de Loo, A, 1995) |
| "Aim of the present study was to assess the efficacy and safety of flecainide (F) and sotalol (S) for the prevention of recurrences of paroxysmal atrial fibrillation (PAF)." | 5.08 | [A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation]. ( Burattini, M; Carunchio, A; Ceci, V; Fera, MS; Galati, A; Greco, G; Mazza, A, 1995) |
| "We randomized 61 patients with paroxysmal atrial fibrillation (AF) ( < 48 hours from onset) to either sotalol or quinidine treatment." | 5.08 | Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). ( Halinen, MO; Huttunen, M; Paakkinen, S; Tarssanen, L, 1995) |
| "This study determined the effect of sotalol on atrial function after electrical cardioversion of atrial fibrillation." | 5.08 | Aggravation of postcardioversion atrial dysfunction by sotalol. ( Falk, RH; Pollak, A, 1995) |
| "To assess the propafenone and sotalol efficacy in the prevention of paroxysmal atrial fibrillation (FA) we enrolled, in a double blind placebo controlled study over 1 year, 300 patients (168 males); mean age 52." | 5.08 | [Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study]. ( Bellandi, F; Cantini, F; Dabizzi, RP; Niccoli, L; Palchetti, R, 1996) |
| "The main goal of this study is to evaluate the safety and efficacy of propafenone versus sotalol as an initial choice of treatment in patients with symptomatic paroxysmal atrial fibrillation (AF), according to a double-blind randomized system." | 5.08 | Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. ( Chang, MS; Chen, SA; Chen, YJ; Cheng, JJ; Chiang, CE; Fong, AN; Huang, JL; Lee, SH; Tai, CT; Wen, ZC; Yu, WC, 1997) |
| "Sotalol's usefulness in treatment of atrial fibrillation and atrial flutter is unproven." | 5.08 | Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. ( Ferrick, KJ; Fisher, JD; Gallik, DM; Kim, SG; Roth, JA, 1997) |
| "To compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation (AF), 70 patients were entered into a randomized, double-blind study." | 5.08 | Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. ( Igoumenidis, NE; Kanoupakis, EM; Kochiadakis, GE; Marketou, ME; Solomou, MC; Vardas, PE, 1998) |
| "To analyze the recurrences of atrial fibrillation in patients treated with sotalol or quinidine." | 5.08 | [Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP]. ( de Paola, AA; Veloso, HH, 1998) |
| "This study sought to compare the efficacy and safety of intravenous flecainide and sotalol for immediate cardioversion of atrial fibrillation." | 5.08 | Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. ( Ebner, A; Gatterer, E; Gattermeier, M; Heinze, G; Hohenwallner, W; Kratzer, H; Kuhn, P; Lenz, K; Poelzl, G; Reisinger, J; Slany, J; Wiesinger, K; Zeindlhofer, E, 1998) |
| "Thus, a selective approach based on a clinical risk prediction algorithm should improve the cost-effectiveness and safety of low-dose sotalol in the prevention of atrial fibrillation after coronary bypass surgery." | 5.08 | Selective versus non-selective antiarrhythmic approach for prevention of atrial fibrillation after coronary surgery: is there a need for pre-operative risk stratification? A prospective placebo-controlled study using low-dose sotalol. ( Buser, P; Huber, M; Osswald, S; Pfisterer, M; Schmidhauser, C; Skarvan, K; Stulz, P; Weber, UK, 1998) |
| "The purpose of our study (conducted between August 1995 and September 1996) was to evaluate prospectively the efficacy of intravenous administration (in 10 min) of sotalol, flecainide or the combination of these drugs to restore sinus rhythm in patients (without cardiac/pulmonary failure) who came to the First Heart Aid of our hospital with atrial fibrillation lasting less than 24 h." | 5.08 | Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide. ( Braat, SH; Heymeriks, J; Peters, FP; Wellens, HJ, 1998) |
| "To compare the efficacy and safety of a single dose of ibutilide, a new class III antiarrhythmic drug, with that of DL-sotalol in terminating chronic atrial fibrillation or flutter in haemodynamically stable patients." | 5.08 | Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. ( Golitsyn, SR; Harry, JD; Perry, KT; Ruda, MY; Stangl, K; Steinbeck, G; Touboul, P; Van Wijk, LV; Vos, MA; Wellens, HJ, 1998) |
| "To establish the value of adjuvant dl-sotalol to digoxin for control of the ventricular response in chronic atrial fibrillation, 60 patients were evaluated in a multicenter, randomized, double-blind, parallel, placebo-controlled study." | 5.07 | Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group. ( Bellinger, R; Brodsky, M; Powers, L; Saini, R; Weiss, R; Zoble, R, 1994) |
| "This study investigated the hemodynamic effects of oral sotalol during both sinus rhythm and paroxysmal atrial fibrillation." | 5.07 | Hemodynamic effects of oral sotalol during both sinus rhythm and atrial fibrillation. ( Alboni, P; Chioin, R; Fucà, G; Paparella, N; Pedini, I; Razzolini, R; Scarfò, S, 1993) |
| "This open, parallel-group study compares quinidine and sotalol treatment for maintenance of sinus rhythm after direct current conversion of patients with chronic atrial fibrillation." | 5.06 | Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. ( Edvardsson, N; Juul-Möller, S; Rehnqvist-Ahlberg, N, 1990) |
| "The efficacy of sotalol in treating acute atrial fibrillation and flutter after open heart surgery was compared with that of a digoxin/disopyramide combination." | 5.05 | Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. ( Campbell, TJ; Gavaghan, TP; Morgan, JJ, 1985) |
| " β blockers, alone or in combination with digoxin, or non-dihydropyridine calcium-channel blockers (not in heart failure) effectively lower the heart rate." | 4.93 | Rate control in atrial fibrillation. ( Crijns, HJ; Olshansky, B; Rienstra, M; Van Gelder, IC, 2016) |
| "To assess the clinical and cost-effectiveness of magnesium sulphate compared with sotalol, and to assess the clinical effectiveness of magnesium sulphate compared with placebo in the prevention of atrial fibrillation (AF) in patients who have had a coronary artery bypass graft (CABG)." | 4.84 | Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. ( Frampton, GK; Jones, J; Price, A; Shepherd, J; Tanajewski, L; Turner, D, 2008) |
| " Most recently, the introduction of dofetilide has widened the therapeutic options in patients with severe heart disease, and the Canadian Trial of Atrial Fibrillation indicated the superior efficacy of amiodarone at low doses." | 4.82 | Antiarrhythmic drug therapy of atrial fibrillation. ( Mounsey, JP; VerNooy, RA, 2004) |
| "Many clinicians choose sotalol for the prevention of recurrences of atrial fibrillation (AF) as an alternative to quinidine, which has been associated with an increase in long-term mortality." | 4.80 | Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation. ( Bauman, J; Southworth, MR; Viana, M; Zarembski, D, 1999) |
| "In summary, the Class III antiarrhythmic agents amiodarone and sotalol are effective in restoring sinus rhythm in patients with chronic atrial fibrillation with a higher effectiveness of amiodarone." | 4.79 | Indications and limitations of class II and III antiarrhythmic drugs in atrial fibrillation. ( Hohnloser, SH, 1994) |
| " In patients with successful DC conversion of chronic atrial fibrillation, sotalol proved to be as effective as quinidine in maintaining sinus rhythm but was better tolerated and provided beneficial rate control during atrial fibrillation in those patients who relapsed." | 4.78 | Comparison of class I and class III action in atrial fibrillation. ( Edvardsson, N, 1993) |
| "Among the drugs recommended to prevent recurrences of atrial fibrillation after external electric shock, antiarrhythmic agents of classes Ia (quinidine, disopyramide), Ic (cibenzoline, flecainide, propafenone) and III (sotalol) seem to have the same effectiveness in maintaining the sinus rhythm in about 50 percent of the cases after 6 months and one year." | 4.78 | [Antiarrhythmic treatment after reduction of atrial fibrillation by external shock]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Theolade, R, 1993) |
| "Oral sotalol is a class III antiarrhythmic commonly used for the maintenance of sinus rhythm in patients with atrial fibrillation (AF)." | 4.31 | Protocol Development and Initial Experience With Intravenous Sotalol Loading for Atrial Arrhythmias. ( Bunch, TJ; Dechand, J; Feuerborn, ML; Freedman, RA; Groh, C; Navaravong, L; Ranjan, R; Steinberg, BA; Torre, M; Vadlamudi, RS; Varela, D, 2023) |
| "The DASH-AF (Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation) trial evaluates the safety and feasibility of intravenous (IV) sotalol, achieving a steady state with maximum QTc prolongation within 6 hours instead of the traditional 5-dose inpatient oral (PO) titration." | 4.31 | Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With Atrial Fibrillation (DASH-AF). ( Ahmed, A; Atkins, D; Bawa, D; Bommana, S; Bush, J; Charate, R; Darden, D; Garg, J; Gopinathannair, R; Kabra, R; Kennedy, R; Koreber, S; Lakkireddy, D; Mohanty, S; Natale, A; Park, P; Pothineni, NVK; Seo, BW; Tummala, R; Vasamreddy, C, 2023) |
| "Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk for bleeding." | 4.31 | Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. ( Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E, 2023) |
| "Sotalol and dronedarone are both used for maintenance of sinus rhythm for patients with atrial fibrillation." | 4.31 | Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fibrillation. ( Blomström-Lundqvist, C; Camm, AJ; Din, N; Fan, J; Kabadi, S; Kowey, P; Pundi, K; Rashkin, J; Sandhu, AT; Singh, JP; Turakhia, MP; Wieloch, M, 2023) |
| "Use of d,l-sotalol for rhythm control in patients with atrial fibrillation (AF) has raised safety concerns." | 4.31 | Mortality and ventricular arrhythmias in patients on d,l-sotalol for rhythm control of atrial fibrillation: A nationwide cohort study. ( Darpo, B; Frick, M; Järnbert-Petersson, H; Lenhoff, H; Tornvall, P, 2023) |
| "There exists variability in the administration of in-patient sotalol therapy for symptomatic atrial fibrillation (AF)." | 4.12 | Economics and outcomes of sotalol in-patient dosing approaches in patients with atrial fibrillation. ( B Muhlestein, J; Burnham, TS; Jared Bunch, T; L Anderson, J; L Bair, T; Steinberg, BA; T May, H; U Knowlton, K; Varela, DL, 2022) |
| " Arrhythmias for which sotalol was initiated included atrioventricular reciprocating tachycardia/atrioventricular nodal reciprocating tachycardia (n = 105 [55%]), atrial flutter (n = 31 [16%]), ectopic atrial tachycardia (n = 26 [14%]), VT (n = 21 [11%]), and atrial fibrillation (n = 7 [4%])." | 3.96 | Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population. ( Abrams, DJ; Alexander, ME; Bevilacqua, LM; Bezzerides, VJ; Chandler, SF; Chu, E; DeWitt, ES; Mah, DY; Triedman, JK; Walsh, EP; Whitehill, RD, 2020) |
| "We aimed to evaluate the effectiveness and safety of dronedarone versus sotalol in real-world practice in Asian patients with atrial fibrillation (AF)." | 3.96 | Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study. ( Choi, EK; Kim, JA; Kim, JH; Kwon, TY; Lee, SR; Lee, YE; Oh, S, 2020) |
| "To evaluate the effect of sotalol on heart rate (HR), QT interval, atrial fibrillatory rate, and success of cardioversion in horses with naturally occurring chronic atrial fibrillation (AF)." | 3.88 | Effect of sotalol on heart rate, QT interval, and atrial fibrillation cycle length in horses with atrial fibrillation. ( Broux, B; De Clercq, D; Decloedt, A; Deprez, P; van Loon, G; Van Steenkiste, G; Ven, S; Vera, L, 2018) |
| "In this clinical setting, we found that thiazides, vessel-active calcium channel blockers, and nonselective beta blockers (specifically sotalol) were associated with a lower risk of incident CHF among patients with atrial fibrillation." | 3.88 | Associations between relevant cardiovascular pharmacotherapies and incident heart failure in patients with atrial fibrillation: a cohort study in primary care. ( Ärnlöv, J; Carlsson, AC; Holzmann, MJ; Sundquist, J; Sundquist, K; Wändell, P, 2018) |
| "Dronedarone was the only anti-arrhythmic drug with significantly lower risk for arrhythmic death, sustained ventricular arrhythmia or ICD implantation than sotalol among patients with atrial fibrillation." | 3.88 | Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs. ( Friberg, L, 2018) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 3.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "To evaluate the efficacy of sotalol depending on the magnitude of changes in adrenal responsiveness and autonomic nervous system tone in patients with paroxysmal atrial fibrillation (AF)." | 3.83 | [A change in adrenal responsiveness in sotalol-treated patients with paroxysmal atrial fibrillation depending on autonomic nervous system tone]. ( Afanasyev, SA; Batalov, RE; Borisova, EV; Kisteneva, IV; Popov, SV; Rebrova, TY, 2016) |
| "Sotalol and amiodarone are commonly prescribed antiarrhythmics for the treatment of post-operative atrial fibrillation (POAF)." | 3.83 | Mortality risk of sotalol and amiodarone for post-CABG atrial fibrillation. ( Brophy, JM; Johnson, SM, 2016) |
| "To estimate cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation (AF)." | 3.81 | Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia. ( Jankovic, SM; Kostic, M; Paunovic, D; Tesic, D, 2015) |
| "Inpatient antiarrhythmic drug initiation for atrial fibrillation is mandated for dofetilide (DF) and is often performed for sotalol (SL), particularly if proarrhythmia risk factors are present." | 3.81 | Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation. ( Agusala, K; Caprio, T; Kulkarni, C; Oesterle, A; Passman, R; Subacius, H, 2015) |
| "Retrospective analysis of 2 double-blind, parallel-group trials (EURIDIS [European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm] and ADONIS [American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm]) comparing the efficacy and safety of dronedarone with placebo over 12 months." | 3.80 | Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. ( Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D, 2014) |
| "Ranolazine is evaluated for antiarrhythmic therapy of atrial fibrillation (AF)." | 3.79 | Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation. ( Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T, 2013) |
| "In several clinical and pre-clinical studies, application of ranolazine (RAN) led to suppression of atrial fibrillation (AF)." | 3.79 | Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness. ( Belardinelli, L; Breithardt, G; Eckardt, L; Frommeyer, G; Ghezelbash, S; Milberg, P; Osada, N; Rajamani, S; Razvan, R, 2013) |
| " dl-Sotalol (SOT) is a β-blocker commonly used in the rhythm-control treatment of atrial fibrillation." | 3.78 | Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. ( Antzelevitch, C; Gibson, JK; Lynch, JJ; Pourrier, M; Sicouri, S, 2012) |
| "Due to risk of serious adverse drug events (ADEs) sotalol use is limited in renal insufficiency and heart failure." | 3.77 | Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement. ( Finks, SW; Manguso, AH; Rogers, KC, 2011) |
| "An 82-year-old woman with persistent atrial fibrillation underwent successful electrical cardioversion and was begun on sotalol." | 3.76 | Sotalol and a broken heart. ( Friedman, PL; Matas, N; Montgomery, S, 2010) |
| " The aim of this study was to determine the effects of IPC versus intravenous (IV) d,l-sotalol and flecainide infusion on transmural atrial electrophysiology and sustained atrial fibrillation (AF) in the goat." | 3.75 | Effects of intrapericardial sotalol and flecainide on transmural atrial electrophysiology and atrial fibrillation. ( Accord, RE; Allessie, MA; Hermans, JJ; Maessen, JG; Schotten, U; Smits, JF; van Brakel, TJ, 2009) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 3.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "This study evaluated antiarrhythmic effects of d,l-sotalol in a canine atrial fibrillation (AF) model with left ventricular dysfunction." | 3.75 | d,l-Sotalol reverses abbreviated atrial refractoriness and prevents promotion of atrial fibrillation in a canine model with left ventricular dysfunction induced by atrial tachypacing. ( Fujiki, A; Hashimoto, N; Inoue, H; Mizumaki, K; Nakatani, Y; Sakabe, M; Sakamoto, T, 2009) |
| "Sotalol is a class III antiarrhythmic agent that is highly effective for tachyarrhythmias in adults, but its efficacy in patients with congenital heart disease (CHD) remains unclear." | 3.74 | Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease. ( Kamakura, S; Kurosaki, K; Miyazaki, A; Ohuchi, H; Yagihara, T; Yamada, O, 2008) |
| "Pharmacotherapy of atrial fibrillation has changed towards increased beta-blocker use with a coincident decrease in the use of other rate-limiting drugs and sotalol." | 3.74 | Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. ( Abildstrom, SZ; Folke, F; Friberg, J; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Madsen, M; Poulsen, HE; Rasmussen, S; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2008) |
| " Antiarrhythmic therapy with sotalol at 240 mg/day was started, and after 48 h the patient experienced several episodes of sustained torsade de pointes, dramatic marked QT interval prolongation and negative T wave, in absence of overt cardiac disease, renal failure, electrolyte abnormalities or baseline QT interval prolongation." | 3.73 | Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease. ( Boldini, A; Brentana, L; D'Aloia, A; Dei Cas, L; Faggiano, P; Pedrinazzi, C; Procopio, R, 2005) |
| "The combination of sotalol and magnesium can significantly reduce the incidence of post-operative atrial fibrillation following coronary surgery." | 3.73 | Does prophylactic sotalol and magnesium decrease the incidence of atrial fibrillation following coronary artery bypass surgery: a propensity-matched analysis. ( Aerra, V; Fabri, BM; Grayson, AD; Kuduvalli, M; Moloto, AN; Oo, AY; Srinivasan, AK, 2006) |
| "We present 4 patients with atrial fibrillation treated with sotalol who developed torsade de pointes due to marked prolongation of the QT interval." | 3.72 | A case series of sotalol-induced torsade de pointes in patients with atrial fibrillation--a tale with a twist. ( Chua, T; Hsu, LF; Kam, RM; Tan, HH; Teo, WS, 2003) |
| "To determine how well dofetilide and Betapace AF (sotalol, approved solely for atrial fibrillation and atrial flutter), with their detailed dosing and monitoring guidelines for safety, were accepted into clinical practice during the 2 calendar years after their introduction." | 3.72 | New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance. ( Kramer, JM; LaPointe, NM; Pamer, CA, 2003) |
| "To analyze action of digoxin and some non-digitalis drugs (beta-blockers, verapamil, amiodarone, d,l-sotalol) and their combinations on electrical activity of atria, frequency and structure of ventricular rhythm in patients with permanent atrial fibrillation." | 3.72 | [Correction of rate and structure of ventricular rhythm in permanent atrial fibrillation: a novel pathogenetic approach]. ( Blagova, OV; Bogdanova, EA; Nedostup, AV; Platonova, AA, 2004) |
| "In experimental studies, sotalol has limited class III action in the electrically remodeled atrium and did not prevent atrial fibrillation (AF) induction." | 3.71 | Electrophysiologic actions of dl-sotalol in patients with persistent atrial fibrillation. ( Lau, CP; Tse, HF, 2002) |
| "To compare the effects of class Ic and III antiarrhythmic agents on the termination and prevention of atrial fibrillation, the present study investigated the use-dependent electrophysiological effects of flecainide, nifekalant and d,l-sotalol on the human atrium." | 3.71 | Frequency-dependent electrophysiological effects of flecainide, nifekalant and d,l-sotalol on the human atrium. ( Kanmatuse, K; Kojima, T; Kunimoto, S; Masaki, R; Nakai, T; Oshikawa, N; Ozawa, Y; Saito, S; Watanabe, H; Watanabe, I, 2001) |
| "Clinical trials suggest that sotalol and dofetilide are much more effective in preventing atrial fibrillation (AF) than in terminating it." | 3.71 | The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF. ( Derakhchan, K; Nattel, S; Talajic, M; Villemaire, C, 2001) |
| "In a 68-year-old woman with severe chronic hepatitis an extensive investigation revealed no other cause than the use of sotalol for 10 months due to atrial fibrillation." | 3.71 | [Chronic hepatitis ascribed to the use of sotalol]. ( Janssens, AR; Kootte, AM; Ouwehand, DK; van Leeuwen, AM, 2001) |
| "We sought to determine the yield of in-hospital monitoring for detection of significant arrhythmia complications in patients starting sotalol therapy for atrial arrhythmias and to identify factors that might predict safe outpatient initiation." | 3.70 | Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. ( Chung, MK; Jaeger, FJ; Kidwell, GA; Miller, DP; Morant, VA; Niebauer, MJ; Pinski, SL; Schweikert, RA; Tchou, PJ; Trohman, RG; Wilkoff, BL, 1998) |
| " She had used sotalol 80 mg once daily for three years without any episodes of proarrhythmia or other adverse effects." | 3.70 | T wave alternans after sotalol: evidence for increased sensitivity to sotalol after conversion from atrial fibrillation to sinus rhythm. ( Tan, HL; Wilde, AA, 1998) |
| "To study the incidence and mode of onset of early reinitiation of atrial fibrillation (ERAF) following successful internal cardioversion of chronic atrial fibrillation, and to determine the effects of sotalol in the prevention of ERAF." | 3.70 | Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol. ( Ayers, GM; Lau, CP; Tse, HF, 1999) |
| "This study was designed to evaluate and compare the effects of oral sotalol for the treatment of vagal and adrenergic paroxysmal atrial fibrillation (PAF)." | 3.70 | Cardioversion with sotalol in selected patients with vagally and adrenergically mediated paroxysmal atrial fibrillation. ( Aslan, O; Bayata, S; Postaci, N; Yeşil, M; Yücel, O, 1999) |
| "This study was undertaken to assess the effects of sotalol on the transthoracic cardioversion energy requirement for chronic atrial fibrillation (AF) and on the atrial electrograms during AF recorded by two basket electrodes." | 3.70 | Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: assessment of the electrophysiological effects by biatrial basket electrodes. ( Huang, SK; Lai, LP; Lien, WP; Lin, JL; Tseng, YZ, 2000) |
| " 1 and 2, atrial fibrillation was treated with either quinidine or quinidine and sotalol in combination." | 3.69 | Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. ( Faber, TS; Hohnloser, S; Just, H; Van de Loo, A; Zehender, M, 1994) |
| "To investigate the effects of low dose sotalol on the signal averaged surface P wave in patients with paroxysmal atrial fibrillation." | 3.69 | Effect of low dose sotalol on the signal averaged P wave in patients with paroxysmal atrial fibrillation. ( Cooper, J; de Bono, DP; Garratt, CJ; Stafford, PJ; Vincent, R, 1995) |
| "The aim of this study was to evaluate of oral sotalol hydrochloride effects on atrial signal-averaged ECG (ASAECG) during time- and frequency-domain analysis in patients with paroxysmal atrial fibrillation (PAF) during ischemic heart disease (IHD)." | 3.69 | [The effect of sotalol hydrochloride therapy on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. ( Banasiak, W; Fuglewicz, A; Kałka, D; Lacheta, W; Pieróg, M; Ponikowski, P; Telichowski, A; Telichowski, C; Wiech, K; Zeborowski, J, 1996) |
| "We evaluated the effects of representative class Ia (procainamide), Ic (propafenone), and III (sotalol) antiarrhythmic drugs on sustained cholinergic atrial fibrillation and atrial electrophysiological properties in anesthetized, open-chest dogs." | 3.68 | Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness. ( Bourne, GW; Nattel, S; Talajic, M; Villemaire, C; Wang, J; Wang, Z, 1993) |
| "A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation." | 3.68 | Sotalol-induced torsade de pointes: management with magnesium infusion. ( Arstall, MA; Hii, JT; Horowitz, JD; Lehman, RG, 1992) |
| "One hundred nine patients with recurrent episodes of symptomatic atrial fibrillation or flutter, or both, who had failed one to five previous antiarrhythmic drug trials were treated with propafenone and, subsequently, sotalol if atrial fibrillation recurred." | 3.68 | Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. ( Antman, EM; Beamer, AD; Cantillon, C; Friedman, PL; McGowan, N, 1990) |
| "The effects of oral Sotalol were assessed by electrophysiological investigations in 6 patients with ventricular preexcitation (Wolff-Parkinson-White syndrome) and a short anterograde refractory period (less than or equal to 280 ms) of the accessory pathway." | 3.67 | [Effects of oral sotalol on the conduction of accessory atrioventricular pathways]. ( Blanc, JJ; Boschat, J; Ollivier, JP; Penther, P, 1985) |
| "Dronedarone was associated with a statistically significantly lower risk of all-cause death versus sotalol (hazard ratio [HR] = 0." | 3.01 | Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis. ( Blomström-Lundqvist, C; Camm, AJ; Crotty, C; Fazeli, MS; Kowey, PR; Kreidieh, B; Singh, JP; Turakhia, MP, 2023) |
| "Pregnancy is associated with a greater risk of arrhythmias, and patients with a history of arrhythmias are at significant risk of arrhythmia recurrence during pregnancy." | 2.82 | Arrhythmias in Pregnancy. ( Briller, JE; Elkayam, U; Lakkireddy, DR; Mason, PK; Merchant, FM; Patel, H; Pillarisetti, J; Russo, AM; Tamirisa, KP; Vaseghi, M; Volgman, AS, 2022) |
| "Persistent AF and hypertension are independent risk factors for late AF recurrence after pulmonary vein isolation." | 2.79 | Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. ( Balsam, P; Kiliszek, M; Kochanowski, J; Koźluk, E; Lodziński, P; Opolski, G; Piątkowska, A; Piątkowski, R; Scisło, P, 2014) |
| "Sotalol was superior to placebo in step 4 (OR: 2." | 2.74 | Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. ( Reda, D; Singh, BN; Singh, SN; Tang, XC, 2009) |
| "Propafenone was given to Group 1 (G1); sotalol to Group 2 (G2); amiodarone to Group 3 (G3) and diltiazem to Group 4 (G4) at doses of 300 mg/day, 80 mg/day, 400 mg/day and 180 mg/day orally respectively." | 2.73 | [The comparison between the efficiency of different anti-arrhythmic agents in preventing postoperative atrial fibrillation after open heart surgery]. ( Aytekin, S; Aytekin, V; Men, EE; Tuğcu, A; Yildirimtürk, O, 2008) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "Sotalol was initiated." | 2.73 | Bifocal versus unifocal right atrial pacing under plasma level controlled sotalol to prevent atrial fibrillation in patients with symptomatic sinus bradycardia and paroxysmal atrial fibrillation. ( Butter, C; Gerhardt, L; Helms, S; Schlegl, M; Stockburger, M, 2007) |
| "Sudden cardiac death was observed in 16 patients, 8 patients in each group." | 2.72 | Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. ( Crijns, HJ; Hagens, VE; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ, 2006) |
| "Amiodarone was more effective at one year than either sotalol or class I agents for the strategy of maintenance of sinus rhythm without cardioversion." | 2.71 | Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. ( , 2003) |
| "In patients with persistent atrial fibrillation (AF), the efficacy and safety of two anti-arrhythmic drugs in preventing the recurrence of AF after successful direct current (DC) cardioversion was prospectively assessed in a multi-centre double-blind, placebo-controlled, randomised trial using daily trans-telephonic monitoring." | 2.71 | Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. ( Bauer, P; Breithardt, G; Engberding, R; Fetsch, T; Koch, HP; Lukl, J; Meinertz, T; Oeff, M; Seipel, L; Trappe, HJ; Treese, N, 2004) |
| "Many patients with paroxysmal atrial fibrillation (AF) become refractory to antiarrhythmic drugs (AADs)." | 2.71 | Hybrid therapy with right atrial catheter ablation and previously ineffective antiarrhythmic drugs for the management of atrial fibrillation. ( Block, JE; Calkins, H; Cher, D; Kocheril, AG; Sharma, AD; Stubbs, HA, 2005) |
| "However, patients with no symptomatic recurrences of AF had higher scores at 3 months on measures of global well-being than those with recurrences in the first 3 months (7." | 2.70 | Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. ( Connolly, SJ; Dorian, P; Green, M; Newman, D; Paquette, M; Roy, D; Talajic, M, 2002) |
| "The indication to treat symptomatic paroxysmal atrial fibrillation is discussed controversely." | 2.69 | [Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT Study. Executive committee of the investigators representing trial physicians]. ( Koch, HP; Lüderitz, B; Meinertz, T; Patten, M; Sonntag, F, 1999) |
| "Sotalol is an antiarrhythmic agent with combined beta-blocking and class III antiarrhythmic properties." | 2.68 | Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. ( Das, G; Falk, R; Hanyok, JJ; Hardy, SA; Karagounis, L; Platia, E; Sung, RJ; Tan, HL, 1995) |
| "In case of PAF recurrence pts withdrew from the study." | 2.68 | [Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence]. ( Burattini, M; Carunchio, A; Ceci, V; Coletta, C; Fera, MS; Galati, A; Mazza, A, 1997) |
| " If sinus rhythm could not be established at that time, electric cardioversion was performed and the drug was continued in lower dosage thereafter." | 2.67 | [Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation--conversion and 12-month follow-up--a randomized comparison]. ( Betz, P; Kalusche, D; Roskamm, H; Stockinger, J, 1994) |
| "Sotalol is a beta-adrenergic blocking drug with the additional property of lengthening the cardiac action potential." | 2.67 | Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery. ( Dion, R; Evenepoel, M; Evrard, P; Goenen, M; Jacquet, L; Marenne, F; Verhelst, R, 1994) |
| "Sotalol was effective in reducing the incidence of atrial fibrillation." | 2.67 | Oral sotalol reduces the incidence of atrial fibrillation after coronary artery bypass surgery. ( Berggren, H; Edvardsson, N; Nyström, U; Pizzarelli, GP; Rådegran, K, 1993) |
| "Amiodarone was associated with the highest rate of patients experiencing at least one serious adverse event (OR 2." | 2.47 | Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. ( Eckert, L; Freemantle, N; Lafuente-Lafuente, C; Mitchell, S; Reynolds, M, 2011) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "Amiodarone has been demonstrated to be more efficacious than propafenone or sotalol in the Canadian Trial of Atrial Fibrillation." | 2.42 | Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. ( Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL, 2003) |
| "Amiodarone is a highly efficacious antiarrhythmic agent for many cardiac arrhythmias, ranging from atrial fibrillation to malignant ventricular tachyarrhythmias, and seems to be superior to other antiarrhythmic agents." | 2.42 | Arrhythmias in the intensive care patient. ( Brandts, B; Trappe, HJ; Weismueller, P, 2003) |
| " Sotalol requires careful patient selection due to the risk of proarrhythmia and although cardiac effects are rare with amiodarone therapy, potentially serious non-cardiac adverse effects can limit the long-term use of this agent." | 2.41 | The role of class III antiarrhythmic agents in maintaining sinus rhythm. ( Brachmann, J, 2000) |
| "Amiodarone has minimal proarrhythmic risk but has numerous noncardiac toxicities that require frequent monitoring." | 2.41 | A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm. ( Cox, CD; Tsikouris, JP, 2001) |
| "Both amiodarone and sotalol were more effective than placebo treatment in reducing the incidence of postoperative AFF." | 2.41 | Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis. ( Lenz, TL; Mohiuddin, SM; Mooss, AN; Wurdeman, RL, 2002) |
| "Sotalol's ability to suppress ventricular ectopy is similar to that of class I agents and better than that of standard beta-blockers." | 2.40 | Sotalol: An important new antiarrhythmic. ( Anderson, JL; Prystowsky, EN, 1999) |
| "Sotalol has a rapid onset of action, allowing it to be efficacious when used orally shortly after surgery." | 2.40 | Prevention of atrial fibrillation in the postoperative cardiac patient: significance of oral class III antiarrhythmic agents. ( Morady, F, 1999) |
| "This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC." | 1.72 | Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022) |
| "Flecainide was used most frequently (26." | 1.62 | Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65. ( D'Angelo, RN; Goldstein, L; Kalsekar, I; Khanna, R; Rahman, M; Tung, P; Yadalam, S; Yeh, RW; Zimetbaum, PJ, 2021) |
| " The objective of this study was to describe prescribing practices of sotalol and dofetilide and to compare safety outcomes between standard and nonstandard dosing strategies." | 1.56 | Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center. ( Knowles, D; Malloy, R; Ting, C, 2020) |
| "Sotalol hydrochloride was a safe anti-arrhythmic drug in the management of this case." | 1.46 | Atrial fibrillation management in a breeding stallion. ( Burger, D; Dauvillier, J; Heliczer, N; Lorello, O; Mitchell, K; Navas de Solis, C; Schwarzwald, CC, 2017) |
| "In this study, we assessed influence of electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits." | 1.43 | Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits. ( Chiba, T; Kondo, N; Takahara, A, 2016) |
| "Dronedarone has failed to make an impact on AAD prescribing." | 1.43 | The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. ( Ahsan, SY; Di Mario, C; Hayward, C; Lyon, AR; Patel, HC; Patel, K; Rowland, E, 2016) |
| "In conclusion, for patients with paroxysmal atrial fibrillation admitted for dofetilide or sotalol loading, T-wave markers of increased repolarization heterogeneity are measurable within hours after initiation." | 1.40 | Electrocardiographic markers of repolarization heterogeneity during dofetilide or sotalol initiation for paroxysmal atrial fibrillation. ( Dorsey, P; Hayes, M; Kaplan, R; Passman, R; Sauer, AJ; Shah, SJ; Xue, J, 2014) |
| "Amiodarone was the most widely used active compound (82%) and apparently the most effective." | 1.39 | [Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs]. ( Alegret, JM; Freire, F; Romero-Menor, C; Viñolas, X, 2013) |
| " Adverse events (AEs) associated with AADs may influence patient compliance and compromise the management of atrial fibrillation (AF)." | 1.37 | One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis. ( Jhaveri, M; Kim, MH; Klingman, D; Lin, J; Smith, PJ, 2011) |
| " Rhythm control agents are associated with clinically important adverse events." | 1.36 | Rhythm control agents and adverse events in patients with atrial fibrillation. ( Hobbs, FD; Hodgkinson, J; Taylor, CJ, 2010) |
| "Amiodarone or sotalol was used in all postoperative patients for 6 months, except in 8 who had bradycardia." | 1.33 | Ablation of atrial fibrillation using microwave energy--early experience. ( Hamzeh, K; Jamil, H; Kabbani, SS; Murad, G; Sabbagh, A, 2005) |
| "Oral sotalol treatment was started after unsuccessful DC cardioversion and given at least 7 days before renewed cardioversion." | 1.33 | Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation. ( Frick, M; Nergärdh, A; Nordlander, R, 2006) |
| "The current recommended starting dose of sotalol is 80 mg orally twice per day, followed by a judicious increase in dosage every 3 days under continuous telemetry monitoring." | 1.33 | Comparison of a standard versus accelerated dosing regimen for D,L-sotalol for the treatment of atrial and ventricular dysrhythmias. ( Gerling, BR; Greenberg, ML; Holzberger, PT; Jones, DR; Juriansz, GJ; Kim, RJ, 2006) |
| "If the fetal atrial flutter is resistant to these therapies, a combination of other congenital cardiac diseases or organic abnormalities should be considered." | 1.33 | Fetal atrial flutter: a case report and experience of sotalol treatment. ( Chiu, TH; Ho, M; Huang, LC; Hung, YC; Lee, CC; Wu, TH, 2006) |
| "The difference in the time course of AF recurrence in patients with ERAF from those with long AF duration suggests distinct arrhythmogenic mechanisms." | 1.32 | Clinical predictors and time course of arrhythmia recurrence in patients with early reinitiation of atrial fibrillation after successful internal cardioversion. ( Lau, CP; Tse, HF, 2003) |
| " Preprinted order forms or procedural guidelines, as well as computer-assisted dosing programs, can be utilized to prevent inappropriate or miscalculated dosing of these agents, which potentially can cause life-threatening ventricular arrhythmias." | 1.32 | Initiation and monitoring of class III antiarrhythmic agents. ( Freeland, S; Worthy, C; Zolnierz, M, 2003) |
| "The amiodarone was omitted in 17 cases because of its side effects." | 1.32 | [Treatment of atrial fibrillation in a Hungarian hospital department of cardiologic internal medicine at the turn of the millennium]. ( Borbély, M; Dani, G; Erdej, F; Hajdara, I; Katona, A; Márk, L; Nagy, E; Sziklai, G, 2004) |
| "Typical arrhythmias are torsade de pointes occurring during treatment with K(+)-channel inhibitors (e." | 1.31 | [Ion channels and arrhythmias]. ( Borchard, U; Hafner, D, 2000) |
| " The mortality rate in this study was 19% (4 of 21 fetuses; 3 had SVT and 1 had AF); 3 deaths occurred just days after the initiation of sotalol therapy, and 1 occurred after a dosage increase." | 1.31 | Sotalol in the treatment of fetal dysrhythmias. ( Kapusta, L; Kleinman, CS; Meijboom, EJ; Michon, MM; Oudijk, MA; Stoutenbeek, P; Visser, GH, 2000) |
| "The tachyarrhythmias were suppressed by sodium channel blocker, potassium channel blocker or magnesium." | 1.31 | Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation. ( Chang, MS; Chen, SA; Chen, YJ; Lin, CI, 2000) |
| "Average follow up at first AF recurrence was 18." | 1.31 | Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. ( Bacchi Reggiani, L; Bartolotti, M; Biffi, M; Boriani, G; Branzi, A; Zannoli, R, 2002) |
| "Atrial tachyarrhythmias were induced by right atrial burst pacing." | 1.30 | Low energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system. ( Fries, R; Heisel, A; Jung, J; Ozbek, C; Schieffer, H; Sen, S; Stopp, M, 1997) |
| "Ventricular proarrhythmia is avoided provided that shocks are well synchronized to R waves that are not at closely coupled intervals or preceded by long-short cycles." | 1.30 | Initial clinical experience with an implantable human atrial defibrillator. ( Camm, AJ; Ho, DS; Lau, CP; Lee, KL; Lok, NS; Murgatroyd, F; Sopher, M; Tse, HF, 1997) |
| " Conversion to sinus rhythm was achieved in 16 out of 22 hemodynamically stable children with a dosage of 4." | 1.30 | Sotalol for atrial tachycardias after surgery for congenital heart disease. ( Beaufort-Krol, GC; Bink-Boelkens, MT, 1997) |
| "Univariate predictors for recurrence included coronary artery disease (p < 0." | 1.30 | Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol. ( Alt, E; Ammer, R; Ayers, GM; Lehmann, G; Pasquantonio, J; Pütter, K; Schömig, A, 1997) |
| "Recurrence is common, although antiarrhythmic drugs often effectively decrease the number and duration of recurrent AF episodes." | 1.30 | Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation. ( Duytschaever, M; Haerynck, F; Jordaens, L; Tavernier, R, 1998) |
| "Sotalol is a betablocker with additional antiarrythmic properties." | 1.30 | [Sotalol--atrial fibrillation, reduced renal function and sudden death]. ( Bathen, J; Madsen, S, 1998) |
| "Sotalol may inhibit IK." | 1.29 | Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms. ( Hara, Y; Masuda, Y; Mori, K; Nakaya, H; Saito, T, 1995) |
| "Undersensing of ventricular tachyarrhythmias is a potentially serious problem, as it may lead to failure to deliver therapy." | 1.29 | Undersensing during ventricular tachyarrhythmias in a third-generation implantable cardioverter defibrillator: diagnosis using stored electrograms and correction with programming. ( Damle, RS; Kelly, PA; Mann, DE; Reiter, MJ, 1994) |
| "Sotalol dose was not appropriately adjusted for creatinine clearance which is age and gender dependent." | 1.29 | Sotalol proarrhythmia: a report of five cases and an audit of the use of a sotalol in a teaching hospital. ( Basta, MN; Fletcher, PJ; Leitch, JW, 1996) |
| "Sotalol has Class II and III antiarrhythmic effects." | 1.28 | Atrial fibrillation in Wolff-Parkinson-White syndrome: reversal of isoproterenol effects by sotalol. ( Madrid, AH; Maŕin Huerta, EM; Mestre, JL; Moro, C; Novo, L, 1992) |
| "2% after intravenous d-sotalol, but no adverse symptoms developed." | 1.28 | Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias. ( Bigger, JT; Kidwell, GA; Reiffel, JA; Sahar, DI; Squatrito, A, 1989) |
| " Twenty-nine patients with supraventricular tachyarrhythmias were treated on 31 occasions to determine the effective therapeutic dosage and optimal method of administration." | 1.27 | Sotalol infusion in the treatment of supraventricular tachyarrhythmias. ( Harte, M; Horgan, JH; Teo, KK, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (3.40) | 18.7374 |
| 1990's | 86 (26.54) | 18.2507 |
| 2000's | 148 (45.68) | 29.6817 |
| 2010's | 54 (16.67) | 24.3611 |
| 2020's | 25 (7.72) | 2.80 |
| Authors | Studies |
|---|---|
| Rolland, T | 1 |
| Badenco, N | 1 |
| Maupain, C | 1 |
| Duthoit, G | 1 |
| Waintraub, X | 1 |
| Laredo, M | 1 |
| Himbert, C | 1 |
| Frank, R | 1 |
| Hidden-Lucet, F | 1 |
| Gandjbakhch, E | 1 |
| Wetterslev, M | 1 |
| Møller, MH | 1 |
| Granholm, A | 1 |
| Hassager, C | 1 |
| Haase, N | 1 |
| Aslam, TN | 1 |
| Shen, J | 1 |
| Young, PJ | 1 |
| Aneman, A | 1 |
| Hästbacka, J | 1 |
| Siegemund, M | 1 |
| Cronhjort, M | 1 |
| Lindqvist, E | 1 |
| Myatra, SN | 1 |
| Kalvit, K | 1 |
| Arabi, YM | 1 |
| Szczeklik, W | 1 |
| Sigurdsson, MI | 1 |
| Balik, M | 1 |
| Keus, F | 1 |
| Perner, A | 1 |
| Field, ME | 1 |
| Varela, DL | 1 |
| Burnham, TS | 1 |
| T May, H | 1 |
| L Bair, T | 1 |
| Steinberg, BA | 5 |
| B Muhlestein, J | 1 |
| L Anderson, J | 1 |
| U Knowlton, K | 1 |
| Jared Bunch, T | 1 |
| Tamirisa, KP | 2 |
| Elkayam, U | 1 |
| Briller, JE | 1 |
| Mason, PK | 1 |
| Pillarisetti, J | 1 |
| Merchant, FM | 1 |
| Patel, H | 1 |
| Lakkireddy, DR | 1 |
| Russo, AM | 1 |
| Volgman, AS | 1 |
| Vaseghi, M | 1 |
| Wharton, JM | 1 |
| Piccini, JP | 5 |
| Koren, A | 1 |
| Huse, S | 1 |
| Ronk, CJ | 2 |
| Udongwo, N | 1 |
| Desai, D | 1 |
| Kozlik, A | 1 |
| Ilagan, J | 1 |
| Chaughtai, S | 1 |
| Zacks, ES | 1 |
| Reynolds, MR | 1 |
| Bunch, TJ | 2 |
| Kim, H | 1 |
| Wieloch, M | 2 |
| Lip, GYH | 1 |
| Valderrábano, M | 1 |
| Feuerborn, ML | 1 |
| Dechand, J | 1 |
| Vadlamudi, RS | 1 |
| Torre, M | 1 |
| Freedman, RA | 1 |
| Groh, C | 1 |
| Navaravong, L | 1 |
| Ranjan, R | 1 |
| Varela, D | 1 |
| Ken-Opurum, J | 1 |
| Srinivas, SS | 1 |
| Vadagam, P | 1 |
| Faith, L | 1 |
| Park, S | 1 |
| Charland, S | 1 |
| Revel, A | 1 |
| Preblick, R | 1 |
| Lakkireddy, D | 1 |
| Ahmed, A | 1 |
| Atkins, D | 1 |
| Bawa, D | 1 |
| Garg, J | 1 |
| Bush, J | 1 |
| Charate, R | 1 |
| Bommana, S | 1 |
| Pothineni, NVK | 1 |
| Kabra, R | 1 |
| Darden, D | 1 |
| Koreber, S | 1 |
| Tummala, R | 1 |
| Vasamreddy, C | 1 |
| Park, P | 1 |
| Mohanty, S | 1 |
| Gopinathannair, R | 1 |
| Seo, BW | 1 |
| Natale, A | 1 |
| Kennedy, R | 1 |
| Singh, JP | 2 |
| Blomström-Lundqvist, C | 2 |
| Turakhia, MP | 2 |
| Camm, AJ | 3 |
| Fazeli, MS | 1 |
| Kreidieh, B | 1 |
| Crotty, C | 1 |
| Kowey, PR | 5 |
| Ray, WA | 1 |
| Chung, CP | 1 |
| Stein, CM | 1 |
| Smalley, W | 1 |
| Zimmerman, E | 1 |
| Dupont, WD | 1 |
| Hung, AM | 1 |
| Daugherty, JR | 1 |
| Dickson, AL | 1 |
| Murray, KT | 1 |
| Augustin, N | 1 |
| Alvarez, C | 1 |
| Kluger, J | 2 |
| Pundi, K | 1 |
| Fan, J | 1 |
| Kabadi, S | 1 |
| Din, N | 1 |
| Kowey, P | 1 |
| Rashkin, J | 1 |
| Sandhu, AT | 1 |
| Lenhoff, H | 3 |
| Järnbert-Petersson, H | 1 |
| Darpo, B | 4 |
| Tornvall, P | 2 |
| Frick, M | 5 |
| Deering, TF | 2 |
| Reiffel, JA | 3 |
| Solomon, AJ | 1 |
| Ornelas-Loredo, A | 1 |
| Kany, S | 1 |
| Abraham, V | 1 |
| Alzahrani, Z | 1 |
| Darbar, FA | 1 |
| Sridhar, A | 1 |
| Ahmed, M | 1 |
| Alamar, I | 1 |
| Menon, A | 1 |
| Zhang, M | 1 |
| Chen, Y | 1 |
| Hong, L | 1 |
| Konda, S | 1 |
| Darbar, D | 1 |
| Chandler, SF | 1 |
| Chu, E | 1 |
| Whitehill, RD | 1 |
| Bevilacqua, LM | 1 |
| Bezzerides, VJ | 1 |
| DeWitt, ES | 1 |
| Alexander, ME | 1 |
| Abrams, DJ | 1 |
| Triedman, JK | 1 |
| Walsh, EP | 1 |
| Mah, DY | 1 |
| Ting, C | 1 |
| Malloy, R | 1 |
| Knowles, D | 1 |
| Lee, SR | 1 |
| Choi, EK | 1 |
| Kim, JH | 1 |
| Kim, JA | 1 |
| Kwon, TY | 1 |
| Lee, YE | 1 |
| Oh, S | 1 |
| Page, A | 1 |
| Couderc, JP | 1 |
| D'Angelo, RN | 1 |
| Rahman, M | 1 |
| Khanna, R | 1 |
| Yeh, RW | 1 |
| Goldstein, L | 1 |
| Yadalam, S | 1 |
| Kalsekar, I | 1 |
| Tung, P | 1 |
| Zimetbaum, PJ | 2 |
| Mascarenhas, DAN | 1 |
| Mudumbi, PC | 1 |
| Kantharia, BK | 1 |
| Heliczer, N | 1 |
| Mitchell, K | 1 |
| Lorello, O | 1 |
| Dauvillier, J | 1 |
| Burger, D | 1 |
| Schwarzwald, CC | 1 |
| Navas de Solis, C | 1 |
| Khan, I | 1 |
| Patel, HC | 2 |
| Nanayakkara, S | 1 |
| Raju, H | 1 |
| Voskoboinik, A | 1 |
| Mariani, JA | 1 |
| Decloedt, A | 1 |
| Broux, B | 1 |
| De Clercq, D | 1 |
| Deprez, P | 1 |
| Van Steenkiste, G | 1 |
| Vera, L | 1 |
| Ven, S | 1 |
| van Loon, G | 1 |
| Wu, C | 1 |
| Tcherny-Lessenot, S | 1 |
| Dai, W | 1 |
| Wang, Y | 1 |
| Kechemir, H | 1 |
| Gandhi, S | 1 |
| Lin, S | 1 |
| Juhaeri, J | 1 |
| Wändell, P | 1 |
| Carlsson, AC | 1 |
| Holzmann, MJ | 1 |
| Ärnlöv, J | 1 |
| Sundquist, J | 1 |
| Sundquist, K | 1 |
| Friberg, L | 1 |
| Dobrev, D | 1 |
| Aguilar, M | 1 |
| Heijman, J | 1 |
| Guichard, JB | 1 |
| Nattel, S | 10 |
| Chen, JA | 1 |
| Ptaszek, LM | 1 |
| Celano, CM | 1 |
| Beach, SR | 1 |
| Arsenault, KA | 1 |
| Yusuf, AM | 1 |
| Crystal, E | 4 |
| Healey, JS | 1 |
| Morillo, CA | 1 |
| Nair, GM | 1 |
| Whitlock, RP | 1 |
| Frommeyer, G | 2 |
| Milberg, P | 2 |
| Uphaus, T | 1 |
| Kaiser, D | 1 |
| Kaese, S | 1 |
| Breithardt, G | 6 |
| Eckardt, L | 3 |
| Deftereos, S | 1 |
| Giannopoulos, G | 1 |
| Kossyvakis, C | 1 |
| Efremidis, M | 1 |
| Panagopoulou, V | 1 |
| Raisakis, K | 1 |
| Kaoukis, A | 1 |
| Karageorgiou, S | 1 |
| Bouras, G | 1 |
| Katsivas, A | 1 |
| Pyrgakis, V | 1 |
| Stefanadis, C | 1 |
| Thelle, DS | 1 |
| Selmer, R | 1 |
| Gjesdal, K | 1 |
| Sakshaug, S | 1 |
| Jugessur, A | 1 |
| Graff-Iversen, S | 1 |
| Tverdal, A | 1 |
| Nystad, W | 1 |
| Zhao, Y | 1 |
| He, X | 1 |
| Mathew, JP | 1 |
| Fullerton, DA | 1 |
| Hegland, DD | 1 |
| Hernandez, AF | 1 |
| Mills, RM | 1 |
| Klaskala, W | 1 |
| Peterson, ED | 3 |
| Lodziński, P | 1 |
| Kiliszek, M | 1 |
| Koźluk, E | 1 |
| Piątkowska, A | 1 |
| Balsam, P | 1 |
| Kochanowski, J | 1 |
| Scisło, P | 1 |
| Piątkowski, R | 1 |
| Opolski, G | 1 |
| Murin, J | 1 |
| Naditch-Brûlé, L | 1 |
| Brette, S | 1 |
| Chiang, CE | 3 |
| O'Neill, J | 1 |
| Steg, PG | 1 |
| Sauer, AJ | 1 |
| Kaplan, R | 1 |
| Xue, J | 1 |
| Dorsey, P | 1 |
| Hayes, M | 1 |
| Shah, SJ | 1 |
| Passman, R | 2 |
| Al-Khatib, SM | 2 |
| Wojdyla, DM | 1 |
| Shaw, LK | 1 |
| Horton, JR | 1 |
| Lokhnygina, Y | 1 |
| Anstrom, KJ | 1 |
| DeWald, T | 1 |
| Allen-LaPointe, N | 1 |
| Thomas, K | 1 |
| Daubert, JP | 1 |
| Tesic, D | 1 |
| Kostic, M | 1 |
| Paunovic, D | 1 |
| Jankovic, SM | 1 |
| Guerra, F | 1 |
| Hohnloser, SH | 4 |
| Crijns, HJ | 5 |
| Aliot, EM | 1 |
| Radzik, D | 1 |
| Roy, D | 7 |
| Connolly, S | 2 |
| Capucci, A | 2 |
| Allen LaPointe, NM | 1 |
| Dai, D | 1 |
| Thomas, L | 1 |
| Agusala, K | 1 |
| Oesterle, A | 1 |
| Kulkarni, C | 1 |
| Caprio, T | 1 |
| Subacius, H | 1 |
| Qin, D | 1 |
| Leef, G | 1 |
| Alam, MB | 1 |
| Rattan, R | 1 |
| Munir, MB | 1 |
| Patel, D | 1 |
| Khattak, F | 1 |
| Adelstein, E | 1 |
| Jain, SK | 1 |
| Saba, S | 1 |
| Barrell, EA | 1 |
| Fiorenza, LR | 1 |
| Perkins, GA | 1 |
| Kraus, MS | 1 |
| Ferber, G | 1 |
| Rosenqvist, M | 2 |
| Borisova, EV | 1 |
| Afanasyev, SA | 1 |
| Rebrova, TY | 1 |
| Kisteneva, IV | 1 |
| Batalov, RE | 1 |
| Popov, SV | 1 |
| Chiba, T | 1 |
| Kondo, N | 1 |
| Takahara, A | 1 |
| Johnson, SM | 1 |
| Brophy, JM | 1 |
| Hayward, C | 1 |
| Patel, K | 1 |
| Di Mario, C | 1 |
| Lyon, AR | 1 |
| Ahsan, SY | 1 |
| Rowland, E | 1 |
| Van Gelder, IC | 4 |
| Rienstra, M | 2 |
| Olshansky, B | 1 |
| Chouchoulis, K | 1 |
| Chiladakis, J | 1 |
| Koutsogiannis, N | 1 |
| Davlouros, P | 1 |
| Kaza, M | 1 |
| Alexopoulos, D | 1 |
| Li, X | 1 |
| Zhang, Y | 2 |
| Liu, H | 1 |
| Jiang, H | 2 |
| Ge, H | 1 |
| Men, EE | 1 |
| Yildirimtürk, O | 1 |
| Tuğcu, A | 1 |
| Aytekin, V | 1 |
| Aytekin, S | 1 |
| Shepherd, J | 1 |
| Jones, J | 1 |
| Frampton, GK | 1 |
| Tanajewski, L | 1 |
| Turner, D | 1 |
| Price, A | 1 |
| Botto, G | 1 |
| Molon, G | 1 |
| Spampinato, A | 1 |
| Favale, S | 1 |
| Proclemer, A | 1 |
| Porfilio, A | 1 |
| Marotta, T | 1 |
| Vimercati, M | 1 |
| Boriani, G | 3 |
| Palardy, M | 1 |
| Ducharme, A | 1 |
| Tardif, JC | 1 |
| White, M | 1 |
| Racine, N | 1 |
| Tétreault, K | 1 |
| Dabouz, F | 1 |
| Talajic, M | 8 |
| Miyazaki, A | 1 |
| Ohuchi, H | 1 |
| Kurosaki, K | 1 |
| Kamakura, S | 1 |
| Yagihara, T | 1 |
| Yamada, O | 1 |
| van Brakel, TJ | 1 |
| Hermans, JJ | 1 |
| Accord, RE | 1 |
| Schotten, U | 2 |
| Smits, JF | 1 |
| Allessie, MA | 3 |
| Maessen, JG | 1 |
| Singh, SN | 8 |
| Tang, XC | 6 |
| Reda, D | 1 |
| Singh, BN | 8 |
| Keivanidou, A | 1 |
| Arnaoutoglou, C | 1 |
| Krommydas, A | 1 |
| Papanikolaou, G | 1 |
| Tsiptses, K | 1 |
| Chrisopoulos, C | 1 |
| Kirpizidis, C | 1 |
| Kim, MH | 2 |
| Klingman, D | 2 |
| Lin, J | 2 |
| Pathak, P | 1 |
| Battleman, DS | 1 |
| Lip, GY | 3 |
| Watson, T | 2 |
| Friedman, PL | 3 |
| Montgomery, S | 1 |
| Matas, N | 1 |
| Mihálcz, A | 1 |
| Földesi, C | 1 |
| Kardos, A | 1 |
| Ladunga, K | 1 |
| Szili-Török, T | 1 |
| Sakamoto, T | 1 |
| Fujiki, A | 1 |
| Nakatani, Y | 1 |
| Sakabe, M | 1 |
| Mizumaki, K | 1 |
| Hashimoto, N | 1 |
| Inoue, H | 2 |
| Kapa, S | 1 |
| Nagel, JJ | 1 |
| Jahangir, A | 1 |
| Asirvatham, SJ | 1 |
| Er, F | 1 |
| Nia, AM | 1 |
| Erdmann, E | 1 |
| Venkataraman, G | 1 |
| Strickberger, SA | 1 |
| Camm, J | 1 |
| Crijns, H | 1 |
| Dorian, P | 8 |
| Le Heuzey, JY | 1 |
| Pedrazzini, L | 1 |
| Prystowsky, EN | 2 |
| Salette, G | 1 |
| Schwartz, PJ | 1 |
| Torp-Pedersen, C | 2 |
| Weintraub, W | 1 |
| Taylor, CJ | 1 |
| Hodgkinson, J | 1 |
| Hobbs, FD | 1 |
| Davis, EM | 1 |
| Packard, KA | 2 |
| Hilleman, DE | 2 |
| Kanorskiĭ, SG | 2 |
| Kanorskaia, IuS | 2 |
| Freemantle, N | 1 |
| Lafuente-Lafuente, C | 1 |
| Mitchell, S | 1 |
| Eckert, L | 1 |
| Reynolds, M | 1 |
| Kong, DF | 1 |
| Apostolakis, S | 1 |
| Finks, SW | 1 |
| Rogers, KC | 1 |
| Manguso, AH | 1 |
| Linz, D | 1 |
| Neuberger, HR | 1 |
| Böhm, M | 1 |
| Wirth, K | 1 |
| Kerin, NZ | 1 |
| Jacob, S | 1 |
| Grunnet, M | 1 |
| Sicouri, S | 1 |
| Pourrier, M | 1 |
| Gibson, JK | 1 |
| Lynch, JJ | 1 |
| Antzelevitch, C | 1 |
| Franz, MR | 2 |
| Smith, PJ | 1 |
| Jhaveri, M | 1 |
| Kumar, S | 1 |
| Sutherland, F | 1 |
| Morton, JB | 1 |
| Lee, G | 1 |
| Morgan, J | 1 |
| Wong, J | 1 |
| Eccleston, DE | 1 |
| Voukelatos, J | 1 |
| Garg, ML | 1 |
| Sparks, PB | 1 |
| Viñolas, X | 1 |
| Freire, F | 1 |
| Romero-Menor, C | 1 |
| Alegret, JM | 1 |
| Kuo, CE | 1 |
| Liang, SF | 1 |
| Lu, SS | 1 |
| Kuan, TC | 1 |
| Lin, CS | 1 |
| Ghezelbash, S | 1 |
| Rajamani, S | 1 |
| Osada, N | 1 |
| Razvan, R | 1 |
| Belardinelli, L | 1 |
| Wong, CK | 1 |
| White, HD | 1 |
| Wilcox, RG | 1 |
| Criger, DA | 1 |
| Califf, RM | 1 |
| Topol, EJ | 1 |
| Ohman, EM | 1 |
| Forlani, S | 2 |
| De Paulis, R | 1 |
| de Notaris, S | 1 |
| Nardi, P | 1 |
| Tomai, F | 1 |
| Proietti, I | 1 |
| Ghini, AS | 1 |
| Chiariello, L | 2 |
| Khairy, P | 1 |
| Tse, HF | 6 |
| Lau, CP | 8 |
| Naccarelli, GV | 2 |
| Wolbrette, DL | 2 |
| Khan, M | 1 |
| Bhatta, L | 1 |
| Hynes, J | 1 |
| Samii, S | 1 |
| Luck, J | 1 |
| Friberg, J | 2 |
| Gadsbøll, N | 2 |
| Zimmer, J | 1 |
| Pezzullo, J | 1 |
| Choucair, W | 1 |
| Southard, J | 1 |
| Kokkinos, P | 1 |
| Karasik, P | 1 |
| Greenberg, MD | 1 |
| Levenson, D | 1 |
| Carlsson, J | 1 |
| Miketic, S | 1 |
| Windeler, J | 1 |
| Cuneo, A | 1 |
| Haun, S | 1 |
| Micus, S | 1 |
| Walter, S | 1 |
| Tebbe, U | 1 |
| Tan, HH | 1 |
| Hsu, LF | 1 |
| Kam, RM | 1 |
| Chua, T | 1 |
| Teo, WS | 1 |
| Reda, DJ | 5 |
| Fye, CL | 1 |
| Ezekowitz, MD | 3 |
| Fletcher, RD | 3 |
| Sharma, SC | 3 |
| Atwood, JE | 4 |
| Jacobson, AK | 3 |
| Lewis, HD | 3 |
| Antman, EM | 4 |
| Falk, RH | 2 |
| Lopez, B | 3 |
| Scherer, M | 1 |
| Dzemali, O | 1 |
| Aybek, T | 1 |
| Wimmer-Greinecker, G | 1 |
| Moritz, A | 1 |
| Trappe, HJ | 4 |
| Brandts, B | 2 |
| Weismueller, P | 1 |
| LaPointe, NM | 1 |
| Pamer, CA | 1 |
| Kramer, JM | 1 |
| Moscarelli, M | 1 |
| Scafuri, A | 1 |
| Pellegrino, A | 1 |
| Lee, JK | 2 |
| Klein, GJ | 2 |
| Krahn, AD | 2 |
| Yee, R | 3 |
| Zarnke, K | 2 |
| Simpson, C | 2 |
| Skanes, A | 2 |
| Healey, J | 1 |
| Connolly, SJ | 4 |
| Khan, IA | 2 |
| Thomas, SP | 1 |
| Guy, D | 1 |
| Wallace, E | 1 |
| Crampton, R | 1 |
| Kijvanit, P | 1 |
| Eipper, V | 1 |
| Ross, DL | 1 |
| Cooper, MJ | 1 |
| Lumer, G | 1 |
| Mangat, I | 1 |
| Sung, RJ | 2 |
| Tereshchenko, SN | 2 |
| Bulanova, NA | 1 |
| Kositsyna, IV | 1 |
| Morozova, MN | 2 |
| Uteshev, IuA | 2 |
| Sanjuán, R | 1 |
| Blasco, M | 1 |
| Carbonell, N | 1 |
| Jordá, A | 1 |
| Núñez, J | 1 |
| Martínez-León, J | 1 |
| Otero, E | 1 |
| VerNooy, RA | 1 |
| Mounsey, JP | 1 |
| Freeland, S | 1 |
| Worthy, C | 1 |
| Zolnierz, M | 1 |
| Nedostup, AV | 1 |
| Blagova, OV | 1 |
| Bogdanova, EA | 1 |
| Platonova, AA | 1 |
| Auer, J | 1 |
| Weber, T | 1 |
| Berent, R | 1 |
| Puschmann, R | 1 |
| Hartl, P | 1 |
| Ng, CK | 1 |
| Schwarz, C | 1 |
| Lehner, E | 1 |
| Strasser, U | 1 |
| Lassnig, E | 1 |
| Lamm, G | 1 |
| Eber, B | 1 |
| Márk, L | 1 |
| Erdej, F | 1 |
| Dani, G | 1 |
| Borbély, M | 1 |
| Sziklai, G | 1 |
| Nagy, E | 1 |
| Hajdara, I | 1 |
| Katona, A | 1 |
| Geertman, H | 1 |
| van der Starre, PJ | 1 |
| Sie, HT | 1 |
| Beukema, WP | 1 |
| van Rooyen-Butijn, M | 1 |
| Fetsch, T | 3 |
| Bauer, P | 1 |
| Engberding, R | 2 |
| Koch, HP | 3 |
| Lukl, J | 2 |
| Meinertz, T | 2 |
| Oeff, M | 1 |
| Seipel, L | 1 |
| Treese, N | 2 |
| Van Bracht, M | 1 |
| Dirkmann, D | 1 |
| Borchard, R | 1 |
| Wickenbrock, I | 1 |
| Prull, MW | 1 |
| Meine, M | 1 |
| Osaka, T | 1 |
| Yamazaki, M | 1 |
| Yokoyama, E | 1 |
| Ito, A | 1 |
| Kodama, I | 1 |
| Humphries, KH | 1 |
| Kerr, CR | 1 |
| Steinbuch, M | 1 |
| Mooss, AN | 2 |
| Wurdeman, RL | 2 |
| Sugimoto, JT | 1 |
| Lenz, TL | 2 |
| Rovang, KS | 1 |
| Arcidi, JM | 1 |
| Mohiuddin, SM | 2 |
| Kochiadakis, GE | 5 |
| Igoumenidis, NE | 5 |
| Hamilos, ME | 1 |
| Tzerakis, PG | 1 |
| Klapsinos, NC | 1 |
| Chlouverakis, GI | 1 |
| Vardas, PE | 5 |
| DiDomenico, RJ | 1 |
| Massad, MG | 1 |
| Kirchhof, P | 1 |
| Engelen, M | 1 |
| Ribbing, M | 1 |
| Wasmer, K | 1 |
| Haverkamp, W | 1 |
| Harris, CL | 2 |
| Raisch, DW | 2 |
| Kocheril, AG | 1 |
| Calkins, H | 1 |
| Sharma, AD | 1 |
| Cher, D | 1 |
| Stubbs, HA | 1 |
| Block, JE | 1 |
| Nitschmann, S | 1 |
| Antz, M | 1 |
| Kuck, KH | 1 |
| Duytschaever, M | 2 |
| Blaauw, Y | 1 |
| Allessie, M | 1 |
| D'Aloia, A | 1 |
| Faggiano, P | 1 |
| Brentana, L | 1 |
| Boldini, A | 1 |
| Pedrinazzi, C | 1 |
| Procopio, R | 1 |
| Dei Cas, L | 1 |
| Rubinstein, J | 1 |
| Desai, KR | 1 |
| Josephson, ME | 1 |
| Kabbani, SS | 1 |
| Murad, G | 1 |
| Jamil, H | 1 |
| Sabbagh, A | 1 |
| Hamzeh, K | 1 |
| Yan, GX | 1 |
| Shukla, G | 1 |
| Chaudhry, GM | 1 |
| Orlov, M | 1 |
| Hoffmeister, P | 1 |
| Haffajee, C | 1 |
| Veloso, HH | 5 |
| de Paola, AA | 3 |
| Scharf, C | 1 |
| Gorenek, B | 1 |
| Cavusoglu, Y | 1 |
| Goktekin, O | 1 |
| Birdane, A | 1 |
| Kudaiberdieva, G | 1 |
| Ata, N | 1 |
| Unalir, A | 1 |
| Timuralp, B | 1 |
| Nergärdh, A | 1 |
| Nordlander, R | 1 |
| Leaver, SK | 1 |
| Ho, TB | 1 |
| Brunckhorst, CB | 2 |
| Vijayalakshmi, K | 1 |
| Whittaker, VJ | 1 |
| Sutton, A | 1 |
| Campbell, P | 1 |
| Wright, RA | 1 |
| Hall, JA | 1 |
| Harcombe, AA | 1 |
| Linker, NJ | 1 |
| Stewart, MJ | 1 |
| Davies, A | 1 |
| de Belder, MA | 1 |
| Niu, F | 1 |
| Huang, CX | 1 |
| Yang, B | 1 |
| Guo, WL | 1 |
| Chen, YX | 1 |
| Jin, CR | 1 |
| Liu, ZM | 1 |
| Aerra, V | 1 |
| Kuduvalli, M | 1 |
| Moloto, AN | 1 |
| Srinivasan, AK | 1 |
| Grayson, AD | 1 |
| Fabri, BM | 1 |
| Oo, AY | 1 |
| Roberts, R | 1 |
| Gent, M | 1 |
| Israel, CW | 1 |
| Fain, E | 1 |
| Champagne, J | 1 |
| Shantsila, E | 1 |
| Narayan, G | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Lombardi, F | 1 |
| Borggrefe, M | 1 |
| Ruzyllo, W | 1 |
| Lüderitz, B | 4 |
| Hagens, VE | 1 |
| Van Veldhuisen, DJ | 1 |
| Dunning, J | 1 |
| Treasure, T | 1 |
| Versteegh, M | 1 |
| Nashef, SA | 1 |
| Kim, RJ | 1 |
| Juriansz, GJ | 1 |
| Jones, DR | 1 |
| Gerling, BR | 1 |
| Holzberger, PT | 1 |
| Greenberg, ML | 1 |
| Pappone, C | 1 |
| Augello, G | 1 |
| Sala, S | 1 |
| Gugliotta, F | 1 |
| Vicedomini, G | 1 |
| Gulletta, S | 1 |
| Paglino, G | 1 |
| Mazzone, P | 1 |
| Sora, N | 1 |
| Greiss, I | 1 |
| Santagostino, A | 1 |
| LiVolsi, L | 1 |
| Pappone, N | 1 |
| Radinovic, A | 1 |
| Manguso, F | 1 |
| Santinelli, V | 1 |
| Wu, TH | 1 |
| Huang, LC | 1 |
| Ho, M | 1 |
| Lee, CC | 1 |
| Chiu, TH | 1 |
| Hung, YC | 1 |
| Myers, JN | 1 |
| Chuich, NG | 1 |
| Kochetov, AG | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Iwamoto, J | 1 |
| Batcher, EL | 1 |
| Hershman, JM | 1 |
| Gulizia, M | 1 |
| Mangiameli, S | 1 |
| Orazi, S | 1 |
| Chiarandà, G | 1 |
| Piccione, G | 1 |
| Di Giovanni, N | 1 |
| Colletti, A | 1 |
| Pensabene, O | 1 |
| Lisi, F | 1 |
| Vasquez, L | 1 |
| Grammatico, A | 1 |
| Stockburger, M | 1 |
| Gerhardt, L | 1 |
| Helms, S | 1 |
| Schlegl, M | 1 |
| Butter, C | 1 |
| Lee, CH | 1 |
| Nam, GB | 1 |
| Park, HG | 1 |
| Kim, HY | 1 |
| Park, KM | 1 |
| Kim, J | 1 |
| Choi, KJ | 1 |
| Kim, YH | 1 |
| Hansen, ML | 1 |
| Gislason, GH | 1 |
| Abildstrom, SZ | 1 |
| Schramm, TK | 1 |
| Folke, F | 1 |
| Sørensen, R | 1 |
| Rasmussen, S | 1 |
| Poulsen, HE | 1 |
| Køber, L | 1 |
| Madsen, M | 1 |
| Bodrikova, VV | 1 |
| Liakishev, AA | 1 |
| Edvardsson, N | 4 |
| Hirsch, I | 1 |
| Emanuelsson, H | 1 |
| Pontén, J | 1 |
| Olsson, SB | 1 |
| van de Loo, A | 2 |
| Baedeker, F | 1 |
| Carunchio, A | 2 |
| Fera, MS | 2 |
| Mazza, A | 2 |
| Burattini, M | 2 |
| Greco, G | 1 |
| Galati, A | 2 |
| Ceci, V | 2 |
| Hendriksen, O | 1 |
| Petersen, CL | 1 |
| Halinen, MO | 1 |
| Huttunen, M | 1 |
| Paakkinen, S | 1 |
| Tarssanen, L | 1 |
| Reimold, SC | 2 |
| Lamas, GA | 1 |
| Cantillon, CO | 2 |
| Mori, K | 1 |
| Hara, Y | 1 |
| Saito, T | 1 |
| Masuda, Y | 1 |
| Nakaya, H | 1 |
| Kalusche, D | 1 |
| Stockinger, J | 1 |
| Betz, P | 1 |
| Roskamm, H | 1 |
| Pollak, A | 1 |
| Tan, HL | 2 |
| Karagounis, L | 1 |
| Hanyok, JJ | 1 |
| Falk, R | 1 |
| Platia, E | 1 |
| Das, G | 1 |
| Hardy, SA | 1 |
| Daubert, C | 1 |
| Mabo, P | 1 |
| Gras, D | 1 |
| Leclercq, C | 1 |
| Wang, J | 2 |
| Feng, J | 1 |
| Jacquet, L | 1 |
| Evenepoel, M | 1 |
| Marenne, F | 1 |
| Evrard, P | 1 |
| Verhelst, R | 1 |
| Dion, R | 1 |
| Goenen, M | 1 |
| Patrick, GM | 1 |
| Pollock, CA | 1 |
| Ibels, LS | 1 |
| Caterson, RJ | 1 |
| Mann, DE | 1 |
| Kelly, PA | 1 |
| Damle, RS | 1 |
| Reiter, MJ | 1 |
| Nyström, U | 1 |
| Berggren, H | 1 |
| Pizzarelli, GP | 1 |
| Rådegran, K | 1 |
| Brodsky, M | 1 |
| Saini, R | 1 |
| Bellinger, R | 1 |
| Zoble, R | 1 |
| Weiss, R | 1 |
| Powers, L | 1 |
| Faber, TS | 1 |
| Zehender, M | 1 |
| Hohnloser, S | 1 |
| Just, H | 1 |
| Manz, M | 1 |
| Alboni, P | 2 |
| Razzolini, R | 1 |
| Scarfò, S | 1 |
| Paparella, N | 1 |
| Fucà, G | 1 |
| Pedini, I | 1 |
| Chioin, R | 1 |
| Koenig, A | 1 |
| Theolade, R | 1 |
| Chauvin, M | 1 |
| Brechenmacher, C | 1 |
| Bourne, GW | 1 |
| Wang, Z | 1 |
| Villemaire, C | 2 |
| Follath, F | 1 |
| Candinas, R | 1 |
| Frielingsdorf, J | 1 |
| Stafford, PJ | 1 |
| Cooper, J | 1 |
| de Bono, DP | 1 |
| Vincent, R | 1 |
| Garratt, CJ | 1 |
| Iskos, D | 1 |
| Lurie, KG | 1 |
| Adler, SW | 1 |
| Shultz, JJ | 1 |
| Coffeen, PR | 1 |
| Mulligan, KA | 1 |
| Benditt, DG | 2 |
| Bellandi, F | 2 |
| Dabizzi, RP | 2 |
| Niccoli, L | 1 |
| Cantini, F | 1 |
| Palchetti, R | 1 |
| Pill, MW | 1 |
| McCloskey, WW | 1 |
| Basta, MN | 1 |
| Leitch, JW | 1 |
| Fletcher, PJ | 1 |
| Feroze, H | 1 |
| Suri, R | 1 |
| Silverman, DI | 1 |
| Jung, F | 1 |
| DiMarco, JP | 1 |
| Alt, E | 2 |
| Schmitt, C | 2 |
| Ammer, R | 2 |
| Plewan, A | 2 |
| Evans, F | 1 |
| Pasquantonio, J | 2 |
| Ideker, T | 1 |
| Lehmann, G | 3 |
| Pütter, K | 2 |
| Schömig, A | 3 |
| Lee, SH | 2 |
| Chen, SA | 4 |
| Tai, CT | 3 |
| Wen, ZC | 2 |
| Chen, YJ | 2 |
| Yu, WC | 2 |
| Huang, JL | 1 |
| Fong, AN | 1 |
| Cheng, JJ | 1 |
| Chang, MS | 4 |
| Lok, NS | 3 |
| Heisel, A | 2 |
| Jung, J | 2 |
| Fries, R | 1 |
| Stopp, M | 1 |
| Sen, S | 1 |
| Schieffer, H | 2 |
| Ozbek, C | 1 |
| Lee, KL | 1 |
| Ho, DS | 1 |
| Sopher, M | 1 |
| Murgatroyd, F | 1 |
| Coletta, C | 1 |
| Beaufort-Krol, GC | 1 |
| Bink-Boelkens, MT | 1 |
| Telichowski, A | 1 |
| Banasiak, W | 1 |
| Wiech, K | 1 |
| Zeborowski, J | 1 |
| Pieróg, M | 1 |
| Ponikowski, P | 1 |
| Kałka, D | 1 |
| Lacheta, W | 1 |
| Fuglewicz, A | 1 |
| Telichowski, C | 1 |
| Gallik, DM | 1 |
| Kim, SG | 1 |
| Ferrick, KJ | 1 |
| Roth, JA | 1 |
| Fisher, JD | 1 |
| Ayers, GM | 4 |
| Neuzner, J | 1 |
| Fröhlig, G | 1 |
| Rustmann, WC | 1 |
| Carpenter, MT | 1 |
| Harmon, C | 1 |
| Botti, CF | 1 |
| Parikka, H | 1 |
| Toivonen, L | 1 |
| Heikkilä, L | 1 |
| Virtanen, K | 1 |
| Järvinen, A | 1 |
| Haerynck, F | 1 |
| Tavernier, R | 1 |
| Jordaens, L | 1 |
| Lang, V | 1 |
| Merkely, B | 1 |
| Ströbel, JP | 1 |
| Bolz, A | 1 |
| Schaldach, M | 1 |
| Marketou, ME | 3 |
| Solomou, MC | 1 |
| Kanoupakis, EM | 2 |
| Hsieh, MH | 1 |
| Ding, YA | 2 |
| Feng, AN | 1 |
| Kuo, BI | 1 |
| Reisinger, J | 1 |
| Gatterer, E | 1 |
| Heinze, G | 1 |
| Wiesinger, K | 1 |
| Zeindlhofer, E | 1 |
| Gattermeier, M | 1 |
| Poelzl, G | 1 |
| Kratzer, H | 1 |
| Ebner, A | 1 |
| Hohenwallner, W | 1 |
| Lenz, K | 1 |
| Slany, J | 1 |
| Kuhn, P | 1 |
| Chung, MK | 1 |
| Schweikert, RA | 1 |
| Wilkoff, BL | 1 |
| Niebauer, MJ | 1 |
| Pinski, SL | 1 |
| Trohman, RG | 1 |
| Kidwell, GA | 2 |
| Jaeger, FJ | 1 |
| Morant, VA | 1 |
| Miller, DP | 1 |
| Tchou, PJ | 1 |
| Marcus, FI | 1 |
| Weber, UK | 1 |
| Osswald, S | 1 |
| Huber, M | 1 |
| Buser, P | 1 |
| Skarvan, K | 1 |
| Stulz, P | 1 |
| Schmidhauser, C | 1 |
| Pfisterer, M | 1 |
| Peters, FP | 1 |
| Braat, SH | 1 |
| Heymeriks, J | 1 |
| Wellens, HJ | 3 |
| Bathen, J | 1 |
| Madsen, S | 1 |
| Wilde, AA | 1 |
| Anderson, JL | 1 |
| Vos, MA | 1 |
| Golitsyn, SR | 1 |
| Stangl, K | 1 |
| Ruda, MY | 1 |
| Van Wijk, LV | 1 |
| Harry, JD | 1 |
| Perry, KT | 1 |
| Touboul, P | 1 |
| Steinbeck, G | 1 |
| Wijffels, MC | 2 |
| Dorland, R | 2 |
| Patten, M | 1 |
| Sonntag, F | 1 |
| Burschel, G | 1 |
| Podrid, PJ | 2 |
| Southworth, MR | 1 |
| Zarembski, D | 1 |
| Viana, M | 1 |
| Bauman, J | 1 |
| Steeds, RP | 1 |
| Birchall, AS | 1 |
| Smith, M | 1 |
| Channer, KS | 1 |
| Gomes, JA | 1 |
| Ip, J | 1 |
| Santoni-Rugiu, F | 1 |
| Mehta, D | 1 |
| Ergin, A | 1 |
| Lansman, S | 1 |
| Pe, E | 1 |
| Newhouse, TT | 1 |
| Chao, S | 1 |
| Tuinenburg, AE | 1 |
| Van Den Berg, MP | 1 |
| Brügemann, J | 1 |
| De Kam, PJ | 1 |
| Williams, JH | 1 |
| Jin, J | 1 |
| Zucker, R | 1 |
| Browne, K | 1 |
| Chang-Sing, P | 1 |
| Yeşil, M | 1 |
| Bayata, S | 1 |
| Postaci, N | 1 |
| Yücel, O | 1 |
| Aslan, O | 1 |
| Morady, F | 1 |
| Santos, SR | 1 |
| Papini, O | 1 |
| Omosako, CE | 1 |
| Pereira, MD | 1 |
| Quintavalle, TB | 1 |
| Riccio, MF | 1 |
| Kurata, A | 1 |
| Pereira, VA | 1 |
| Di-Pietro, G | 1 |
| Della-Paschoa, OE | 1 |
| Danhof, M | 1 |
| Da-Luz, PL | 1 |
| Eisenberg, MJ | 1 |
| Green, M | 2 |
| Kus, T | 1 |
| Lambert, J | 2 |
| Dubuc, M | 2 |
| Gagné, P | 2 |
| Thibault, B | 2 |
| Lai, LP | 2 |
| Lin, JL | 2 |
| Lien, WP | 2 |
| Tseng, YZ | 2 |
| Huang, SK | 2 |
| Borchard, U | 1 |
| Hafner, D | 1 |
| Lewalter, T | 1 |
| Bharucha, DB | 1 |
| Dell'Orfano, JT | 1 |
| Patel, HM | 1 |
| Luck, JC | 1 |
| Oudijk, MA | 1 |
| Michon, MM | 1 |
| Kleinman, CS | 1 |
| Kapusta, L | 1 |
| Stoutenbeek, P | 1 |
| Visser, GH | 1 |
| Meijboom, EJ | 1 |
| Joseph, AP | 1 |
| Ward, MR | 1 |
| Mast, F | 1 |
| Peters, NS | 1 |
| Ostergren, J | 1 |
| Kaleboubas, MD | 2 |
| Simantirakis, EN | 1 |
| Aggarwal, A | 1 |
| Paquette, M | 2 |
| Newman, D | 2 |
| Couturier, A | 2 |
| Yang, C | 1 |
| Lin, CI | 1 |
| Cosío, FG | 1 |
| Forney, AJ | 1 |
| Schooff, M | 1 |
| Spindler, B | 1 |
| Chrysostomakis, SI | 1 |
| Mavrakis, HE | 2 |
| Watanabe, H | 1 |
| Watanabe, I | 1 |
| Nakai, T | 1 |
| Oshikawa, N | 1 |
| Kunimoto, S | 1 |
| Masaki, R | 1 |
| Kojima, T | 1 |
| Saito, S | 1 |
| Ozawa, Y | 1 |
| Kanmatuse, K | 1 |
| Barbosa, EC | 1 |
| Barbosa, PR | 1 |
| Ginefra, P | 1 |
| de Souza Bomfim, A | 1 |
| Boghossian, SH | 1 |
| da Rocha, PJ | 1 |
| Filho, FM | 1 |
| Brachmann, J | 1 |
| Reddy, P | 1 |
| Kalebubas, MD | 1 |
| Vardakis, KE | 1 |
| Derakhchan, K | 1 |
| Tahapary, GJ | 1 |
| Suttorp, MJ | 1 |
| Coumel, P | 1 |
| Ndrepepa, G | 1 |
| Schreieck, J | 1 |
| Alt, EU | 1 |
| Simonetti, I | 1 |
| Leoncini, M | 1 |
| Frascarelli, F | 1 |
| Giovannini, T | 1 |
| Maioli, M | 1 |
| Matsuura, K | 1 |
| Takahara, Y | 1 |
| Sudo, Y | 1 |
| Ishida, K | 1 |
| Tsikouris, JP | 1 |
| Cox, CD | 1 |
| Kootte, AM | 1 |
| Janssens, AR | 1 |
| Ouwehand, DK | 1 |
| van Leeuwen, AM | 1 |
| Castro, A | 1 |
| Bianconi, L | 1 |
| Santini, M | 1 |
| Burri, H | 1 |
| Biffi, M | 1 |
| Bartolotti, M | 1 |
| Bacchi Reggiani, L | 1 |
| Zannoli, R | 1 |
| Branzi, A | 1 |
| Brignole, M | 1 |
| Menozzi, C | 1 |
| Gasparini, M | 1 |
| Bongiorni, MG | 1 |
| Botto, GL | 1 |
| Ometto, R | 1 |
| Bruna, C | 1 |
| Vincenti, A | 1 |
| Verlato, R | 1 |
| Becker, R | 1 |
| Senges, JC | 1 |
| Bauer, A | 1 |
| Schreiner, KD | 1 |
| Voss, F | 1 |
| Kuebler, W | 1 |
| Schoels, W | 1 |
| Krahn, A | 1 |
| Klein, G | 1 |
| Skanes, AC | 1 |
| Lumer, GB | 1 |
| Frasure-Smith, N | 1 |
| Sleik, K | 1 |
| Ginger, TJ | 1 |
| Yusuf, S | 1 |
| Madrid, AH | 1 |
| Moro, C | 1 |
| Maŕin Huerta, EM | 1 |
| Novo, L | 1 |
| Mestre, JL | 1 |
| Arstall, MA | 1 |
| Hii, JT | 1 |
| Lehman, RG | 1 |
| Horowitz, JD | 1 |
| Inama, G | 1 |
| Furlanello, F | 1 |
| Vergara, G | 1 |
| Guarnerio, M | 1 |
| Braito, G | 1 |
| Nassivera, E | 1 |
| Campbell, TJ | 2 |
| Van Gilst, WH | 1 |
| Hillege, H | 1 |
| Gosselink, AM | 1 |
| Lie, KI | 1 |
| Singh, S | 1 |
| Saini, RK | 1 |
| DiMarco, J | 1 |
| Gold, R | 1 |
| Chen, YW | 1 |
| Feld, GK | 1 |
| Juul-Möller, S | 1 |
| Rehnqvist-Ahlberg, N | 1 |
| Beamer, AD | 1 |
| Cantillon, C | 1 |
| McGowan, N | 1 |
| Bauernfeind, RA | 1 |
| Welch, WJ | 1 |
| Sahar, DI | 1 |
| Bigger, JT | 1 |
| Squatrito, A | 1 |
| Lemery, R | 1 |
| Brugada, P | 1 |
| Havenith, M | 1 |
| Barbour, D | 1 |
| Roberts, WC | 1 |
| Gautam, CS | 1 |
| Lal, R | 1 |
| Pandhi, P | 1 |
| Sharma, PL | 1 |
| Ramsdale, DR | 1 |
| Peterson, C | 1 |
| Bertrix, L | 1 |
| Timour-Chah, Q | 1 |
| Lang, J | 1 |
| Lakhal, M | 1 |
| Faucon, G | 1 |
| Gavaghan, TP | 1 |
| Morgan, JJ | 1 |
| Blanc, JJ | 1 |
| Boschat, J | 1 |
| Ollivier, JP | 1 |
| Penther, P | 1 |
| Teo, KK | 1 |
| Harte, M | 1 |
| Horgan, JH | 1 |
| Prakash, R | 1 |
| Parmley, WW | 1 |
| Allen, HN | 1 |
| Matloff, JM | 1 |
| Gettes, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Association of Postoperative Lactate Levels With Postoperative Atrial Fibrillation in Patients Undergoing Isolated Coronary Artery Bypass Graft Surgery[NCT05448521] | 250 participants (Anticipated) | Observational | 2022-08-15 | Recruiting | |||
| Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement - a Randomized Controlled Trial[NCT05076019] | 266 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Post-Operative Atrial Fibrillation After Surgical Aortic Valve Replacement and the Influence of Statins - Randomized Controlled Trial[NCT05062239] | 100 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | |||
| A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery[NCT05780320] | 242 participants (Anticipated) | Observational | 2022-09-19 | Active, not recruiting | |||
| Pre-Operative Stellate Ganglion to Prevent Post-Operative Atrial Fibrillation[NCT05656170] | 0 participants (Actual) | Interventional | 2023-10-01 | Withdrawn (stopped due to Unable to begin study) | |||
| Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery[NCT05543278] | Phase 4 | 242 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation: a Prospective, Controlled, Randomized Pilot Study[NCT02889562] | Phase 2/Phase 3 | 56 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation[NCT03432663] | Phase 4 | 60 participants (Actual) | Interventional | 2008-08-01 | Completed | ||
| Dual Shock Versus Single Shock Synchronized External Direct Current Cardioversion for Atrial Fibrillation - A Double-blinded Randomized Trial[NCT03943693] | Phase 4 | 100 participants (Actual) | Interventional | 2019-04-01 | Terminated (stopped due to Poor enrollment) | ||
| Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150] | 80 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| [NCT00000556] | Phase 3 | 0 participants | Interventional | 1995-03-31 | Completed | ||
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| CSP #399 - The Effects of Antiarrhythmic Therapy in Maintaining Stability of Sinus Rhythm in Atrial Fibrillation[NCT00007605] | Phase 3 | 706 participants (Anticipated) | Interventional | 1998-04-30 | Completed | ||
| A Randomized Controlled Trial of Prophylactic Pulmonary Vein Isolation as Adjunct to Coronary Artery Bypass Grafting[NCT00338715] | Phase 3 | 193 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Reveal® XT Performance Trial[NCT00680927] | Phase 4 | 247 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication[NCT05939076] | Phase 3 | 220 participants (Anticipated) | Interventional | 2023-08-21 | Not yet recruiting | ||
| Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation[NCT02145546] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-05-31 | Not yet recruiting | ||
| aMsa and amiOdarone Study in cArdiaC Arrest[NCT04997980] | 500 participants (Anticipated) | Observational | 2015-01-01 | Recruiting | |||
| [NCT00257959] | Phase 4 | 400 participants | Interventional | 2001-01-31 | Completed | ||
| A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial[NCT00340314] | Phase 4 | 198 participants | Interventional | 2005-01-31 | Completed | ||
| [NCT00224341] | Phase 4 | 360 participants | Interventional | 2003-11-30 | Recruiting | ||
| Subclinical Postoperative Atrial Fibrillation[NCT02522364] | 150 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | |||
| Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving an Amniotic Membrane Patch Placed on the Epicardial Surface[NCT02193321] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2014-07-31 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Efficacy will be measured by the freedom from stroke during the study period. Events relating to stroke will be adjudicated using pre-determined definitions by independent committee members that remain blinded to the patient's treatment arm. (NCT02889562)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Apixaban | 0 |
| Warfarin | 0 |
Efficacy will be measured by the freedom from thromboembolytic events during the study period. Events relating to thromboembolytic events will be adjudicated using pre-determined definitions by independent committee members that remain blinded to the patient's treatment arm. (NCT02889562)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 0 |
| Warfarin | 0 |
Time in therapeutic range of INR, if on warfarin, (eg. 2-3), measured as a percentage and defined for each patient using the Rosendaal equation (NCT02889562)
Timeframe: 30 days
| Intervention | percentage (Mean) |
|---|---|
| Warfarin | 56.8 |
This will be measured from the date/time of the end of the subject's surgery until the date/time of the patient's discharge from the hospital. This will be measured in hours, to the nearest tenth of an hour. (NCT02889562)
Timeframe: 30 days
| Intervention | hours (Mean) |
|---|---|
| Apixaban | 167.5 |
| Warfarin | 143.1 |
Units of blood or blood products given after the first dose of anticoagulation. (NCT02889562)
Timeframe: 30 days
| Intervention | total units of blood (Number) |
|---|---|
| Apixaban | 6 |
| Warfarin | 2 |
53 reviews available for sotalol and Atrial Fibrillation
| Article | Year |
|---|---|
Arrhythmias in Pregnancy.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Pregnancy; Sotalol; Tachyca | 2022 |
The Future of Antiarrhythmic Drug Therapy: Will Drugs Be Entirely Replaced by Procedures?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Humans; Sotalol; Tachycardia, Ventri | 2022 |
Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Network Meta-An | 2023 |
The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart Failure; Hum | 2023 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Rate control in atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atenolol; Atrial Fibri | 2016 |
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Cost-Benefit Analysis; Database | 2008 |
Atrial fibrillation (acute onset).
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Sotalol | 2008 |
Pharmacologic prophylaxis of postoperative atrial fibrillation in patients undergoing cardiac surgery: beyond beta-blockers.
Topics: Acetylcysteine; Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotens | 2010 |
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Flecainide; Huma | 2011 |
Atrial fibrillation (acute onset).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Sotalol | 2011 |
The efficacy of sotalol in preventing postoperative atrial fibrillation: a meta-analysis.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Drug Therapy, Combination; Electro | 2011 |
New insights into the mechanisms and management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Hu | 2002 |
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Tria | 2003 |
Meta-analysis of antiarrhythmic therapy in the prevention of postoperative atrial fibrillation and the effect on hospital length of stay, costs, cerebrovascular accidents, and mortality in patients undergoing cardiac surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiac Surgica | 2003 |
Arrhythmias in the intensive care patient.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; | 2003 |
Atrial fibrillation after cardiac surgery: update on the evidence on the available prophylactic interventions.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2003 |
Atrial stunning: basics and clinical considerations.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function; Atrial Functi | 2003 |
Cost evaluation of rhythm control methods for atrial fibrillation: evidence from CTAF.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Cost-Benefit Anal | 2003 |
Facilitating electrical cardioversion of persistant atrial fibrillation by antiarrhythmic drugs: update on clinical trial results.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Propafenone; Randomized | 2003 |
[Chronic heart failure and atrial fibrilation: aspects of management].
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmi | 2003 |
Antiarrhythmic drug therapy of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Flecainide; Humans; Phenethyl | 2004 |
Atrial fibrillation after cardiac surgery: evidence on prophylactic interventions.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2003 |
Pharmacologic strategies for prevention of atrial fibrillation after open heart surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II; Anti-Arrhythmia Agents; Atrial Fibrillation | 2005 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
Atrial fibrillation post-cardiac surgery: changing perspectives.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Atrial Fibrillation; Cardiac Surgical | 2006 |
Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Evidence-Based | 2006 |
[Pharmacological therapy for atrial fibrillation after cardiac surgery].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anticoagulants; Atrial Fibrillation; Calcium Channel Blocke | 2007 |
Indications and limitations of class II and III antiarrhythmic drugs in atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trial | 1994 |
Comparison of class I and class III action in atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trial | 1993 |
Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Humans; | 1993 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
[Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Disopyramide; El | 1993 |
[Therapy of atrial fibrillation with class III anti-arrhythmia agents].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Heart Atria; Humans; S | 1993 |
Antiarrhythmic drug therapy in the treatment of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Electrop | 1996 |
Risks of initiating therapy with sotalol for treatment of atrial fibrillation.
Topics: Aged; Ambulatory Care; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flu | 1998 |
Sotalol: An important new antiarrhythmic.
Topics: Action Potentials; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibri | 1999 |
Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Humans; Quinidine; Secondary Preventio | 1999 |
Prevention of atrial fibrillation in the postoperative cardiac patient: significance of oral class III antiarrhythmic agents.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as To | 1999 |
Drug choices in the treatment of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Electric Countershock; Hum | 2000 |
Management and prevention of atrial fibrillation after cardiovascular surgery.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial | 2000 |
Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit An | 2000 |
Post-cardioversion atrial fibrillation: the synthesis of modern concepts?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Electric Countershock; Hear | 2000 |
The role of class III antiarrhythmic agents in maintaining sinus rhythm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Heart Conduction Syst | 2000 |
Does prophylaxis against atrial fibrillation after cardiac surgery reduce length of stay or hospital costs?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Costs and Cost | 2001 |
A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Drug Interactions | 2001 |
New antiarrhythmic drugs for the treatment of atrial fibrillation.
Topics: Aminobenzoates; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, | 2002 |
Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronary Artery Bypas | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Appendage; Atrial Fibrillation; Atrial | 2002 |
Atrial fibrillation. Is there a safe and highly effective pharmacological treatment?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Death, Sudden; Electric Count | 1990 |
Beta adrenergic blocking drugs in the treatment of cardiac arrhythmias.
Topics: Adrenergic beta-Antagonists; Alprenolol; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atrial Fibrillatio | 1970 |
102 trials available for sotalol and Atrial Fibrillation
| Article | Year |
|---|---|
Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2013 |
Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chi-Square Distri | 2014 |
Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Coronary Artery Disea | 2014 |
Reduction over time of QTc prolongation in patients with sotalol after cardioversion of atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Electric Counte | 2016 |
[The comparison between the efficiency of different anti-arrhythmic agents in preventing postoperative atrial fibrillation after open heart surgery].
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Proc | 2008 |
The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Bradycardia; Cardiac Pacing, Artificial; Fem | 2008 |
Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Female; Humans; Male; Middle | 2008 |
Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Combined Mod | 2009 |
Physician stated atrial fibrillation management in light of treatment guidelines: data from an international, observational prospective survey.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channe | 2010 |
Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Confidence Interva | 2012 |
Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Hospit | 2002 |
Combination of sotalol and magnesium prevents atrial fibrillation after coronary artery bypass grafting.
Topics: Aged; Atrial Fibrillation; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administra | 2002 |
Intracardiac low-energy versus transthoracic high-energy direct-current cardioversion of atrial fibrillation: a randomised comparison.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Creatine Kinase; Electric | 2003 |
Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Atriove | 2003 |
Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Atriove | 2003 |
Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Atriove | 2003 |
Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Atriove | 2003 |
Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Endpoint Determination; Humans; Sotalol | 2003 |
Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Endpoint Determination; Humans; Sotalol | 2003 |
Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Endpoint Determination; Humans; Sotalol | 2003 |
Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Endpoint Determination; Humans; Sotalol | 2003 |
Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Female; Heart Ra | 2003 |
Combination therapy for prevention of atrial fibrillation after coronary artery bypass surgery: a randomized trial of sotalol and magnesium.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypa | 2003 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fib | 2003 |
Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Female; Humans; Infusions, I | 2004 |
Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Health Status Indicators; Humans; Propafeno | 2003 |
Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fi | 2004 |
A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgica | 2004 |
Magnesium in addition to sotalol does not influence the incidence of postoperative atrial tachyarrhythmias after coronary artery bypass surgery.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiopulmonary Bypass; Coronary Artery | 2004 |
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blin | 2004 |
Sotalol reverses remodeled action potential in patients with chronic atrial fibrillation but does not prevent arrhythmia recurrence.
Topics: Action Potentials; Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2004 |
Amiodarone versus sotalol for the treatment of atrial fibrillation after open heart surgery: the Reduction in Postoperative Cardiovascular Arrhythmic Events (REDUCE) trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Coronary | 2004 |
Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Propafenone; P | 2004 |
Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation.
Topics: Action Potentials; Adult; Aged; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillation; Elect | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Hybrid therapy with right atrial catheter ablation and previously ineffective antiarrhythmic drugs for the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Combined Modality Therap | 2005 |
Amiodarone versus Sotalol and Propafenone for prevention of immediate recurrence of atrial fibrillation after internal cardioversion: importance of P wave analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Humans; Male | 2006 |
A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Electric C | 2006 |
[Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Admini | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy.
Topics: Activities of Daily Living; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Bl | 2006 |
Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blin | 2006 |
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2006 |
A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; | 2006 |
Exercise capacity in atrial fibrillation: a substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Electric Counter | 2007 |
[Effect of bisoprolol and sotalol on clinical status of patients with proximal form of atrial fibrillation and chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Fibrillation; Bisoprolol; Exercise Test; Female; He | 2007 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Female; Humans; Hyper | 2007 |
A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; | 2008 |
Bifocal versus unifocal right atrial pacing under plasma level controlled sotalol to prevent atrial fibrillation in patients with symptomatic sinus bradycardia and paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Combined Modality Therapy; Cross-Ove | 2007 |
Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibril | 2008 |
[Influence of perindopril, rosuvastatin, or omega-3 polyunsaturated fatty acids on efficacy of antirecurrence therapy with sotalol in patients with persistent atrial fibrillation].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-R | 2007 |
[Circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. Results of the APAF trial].
Topics: Adolescent; Adult; Aged; Amiodarone; Angina, Unstable; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2008 |
Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Drug Administration Schedul | 1995 |
[A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation].
Topics: Adult; Aged; Atrial Fibrillation; Female; Flecainide; Follow-Up Studies; Humans; Male; Middle Aged; | 1995 |
Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial).
Topics: Acute Disease; Adult; Aged; Atrial Fibrillation; Digoxin; Drug Therapy, Combination; Female; Heart R | 1995 |
Risk factors for the development of recurrent atrial fibrillation: role of pacing and clinical variables.
Topics: Atrial Fibrillation; Cardiac Pacing, Artificial; Chronic Disease; Female; Heart Atria; Heart Disease | 1995 |
[Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation--conversion and 12-month follow-up--a randomized comparison].
Topics: Aged; Atrial Fibrillation; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Adminis | 1994 |
Aggravation of postcardioversion atrial dysfunction by sotalol.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Function; Double-Blind Method; Echocardi | 1995 |
Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Dose-Response Relationship, | 1995 |
Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery.
Topics: Administration, Oral; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Cardia | 1994 |
Oral sotalol reduces the incidence of atrial fibrillation after coronary artery bypass surgery.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Atrial Fibrillation; Ch | 1993 |
Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group.
Topics: Atrial Fibrillation; Chronic Disease; Digoxin; Double-Blind Method; Drug Therapy, Combination; Elect | 1994 |
Hemodynamic effects of oral sotalol during both sinus rhythm and atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Cardiac Catheterization; Cardiac Pacing, Art | 1993 |
Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Male; | 1993 |
[Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Electrocardiography; | 1996 |
Sotalol prophylaxis and treatment of atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Sotalol | 1996 |
Effect of electrode position on outcome of low-energy intracardiac cardioversion of atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Catheterizat | 1997 |
Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Evaluation S | 1997 |
Oxygen uptake kinetics and cardiopulmonary performance in lone atrial fibrillation and the effects of sotalol.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Exe | 1997 |
[Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Transesophageal; Female; Flecainide; | 1997 |
Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter.
Topics: Aged; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Female; Hemodynamics; Humans; Male; Midd | 1997 |
Comparison of sotalol and metoprolol in the prevention of atrial fibrillation after coronary artery bypass surgery.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Electrocardiography; Female; He | 1998 |
Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Female; Follow-Up Stud | 1998 |
Effects of antiarrhythmic drugs on variability of ventricular rate and exercise performance in chronic atrial fibrillation complicated with ventricular arrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Chi-Square | 1998 |
[Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Quinidi | 1998 |
Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Electroph | 1998 |
Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Administration Schedule; Female | 1998 |
Selective versus non-selective antiarrhythmic approach for prevention of atrial fibrillation after coronary surgery: is there a need for pre-operative risk stratification? A prospective placebo-controlled study using low-dose sotalol.
Topics: Adult; Aged; Algorithms; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Dose-R | 1998 |
Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Thera | 1998 |
Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 1998 |
[Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT Study. Executive committee of the investigators representing trial physicians].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Doubl | 1999 |
[Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Dis | 1999 |
An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Atrial Fibrillation; Cross-Over Studies; Drug Administr | 1999 |
Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Dou | 1999 |
Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disease-Free Survival; Dose-Response Re | 1999 |
Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of São Paulo.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Female; Heart Rate; Human | 1999 |
A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias.
Topics: Anti-Arrhythmia Agents; Area Under Curve; Atrial Fibrillation; Chromatography, High Pressure Liquid; | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Female; Humans | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Female; Humans | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Female; Humans | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Female; Humans | 2000 |
A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
Topics: Aged; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Digoxin; | 2000 |
The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 2000 |
Atrial pacing for suppression of early reinitiation of atrial fibrillation after successful internal cardioversion.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Electric Count | 2000 |
Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Dist | 2000 |
Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Fem | 2000 |
Is either sotalol or amiodarone more effective than digoxin for converting patients with new-onset atrial fibrillation (AF) to sinus rhythm within 48 hours?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Humans; Sotalol; Treatment Outcome | 2000 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: a prospective, randomized pilot study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Digoxin; | 2000 |
Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart R | 2000 |
Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Circadian | 2001 |
Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Electric Count | 2001 |
Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Surviva | 2001 |
Effect of Sotalol in the prevention of atrial fibrillation following coronary artery bypass grafting.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Fem | 2001 |
An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Catheter Ablat | 2002 |
Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Female; Health Status Indicat | 2002 |
Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Costs and Cost | 2002 |
[Sotalol in the Wolff-Parkinson-White syndrome: an electrophysiological and clinical study].
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrocardiography; Electrophysiology; Fema | 1992 |
Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group.
Topics: Atrial Fibrillation; Chronic Disease; Digoxin; Double-Blind Method; Electrocardiography, Ambulatory; | 1991 |
Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Death, Sudden; Dose-Response Rel | 1990 |
Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial.
Topics: Atrial Fibrillation; Atrial Flutter; Cardiopulmonary Bypass; Clinical Trials as Topic; Digoxin; Diso | 1985 |
169 other studies available for sotalol and Atrial Fibrillation
| Article | Year |
|---|---|
Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy.
Topics: Arrhythmogenic Right Ventricular Dysplasia; Atrial Fibrillation; Defibrillators, Implantable; Flecai | 2022 |
Management of acute atrial fibrillation in the intensive care unit: An international survey.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Intensive Care Units; Sotalol; Surveys and Ques | 2022 |
Intravenous sotalol-A shortcut to success?
Topics: Administration, Intravenous; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Sotalol | 2022 |
Economics and outcomes of sotalol in-patient dosing approaches in patients with atrial fibrillation.
Topics: Aftercare; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Medic | 2022 |
Comparative Safety and Effectiveness of Sotalol Versus Dronedarone After Catheter Ablation for Atrial Fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Humans; Retrospective S | 2022 |
Esophagopericardial Fistula and Pneumopericardium as a Complication of Pulmonary Vein Isolation in a 62-Year-Old Man with Atrial Fibrillation: A Case Report.
Topics: Atrial Fibrillation; Chest Pain; Fistula; Humans; Male; Middle Aged; Pneumopericardium; Pulmonary Ve | 2022 |
Novel methodology for the evaluation of symptoms reported by patients with newly diagnosed atrial fibrillation: Application of natural language processing to electronic medical records data.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Dizziness; Dronedarone; Dyspnea; Electronic Heal | 2023 |
Protocol Development and Initial Experience With Intravenous Sotalol Loading for Atrial Arrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Female; H | 2023 |
A value-based budget impact model for dronedarone compared with other rhythm control strategies.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Sotalol | 2023 |
Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With Atrial Fibrillation (DASH-AF).
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Feasibility Studies; Humans; Prospective Studies | 2023 |
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; | 2023 |
Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Femal | 2023 |
Mortality and ventricular arrhythmias in patients on d,l-sotalol for rhythm control of atrial fibrillation: A nationwide cohort study.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Humans; So | 2023 |
Chapter 5: Guideline Recommendations: Which AAD and for Whom?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Failure; Humans; Sotalol; Stroke Volume; United S | 2023 |
Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs.
Topics: Aged; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Diet, High-Fat; Disease Models, Animal; | 2020 |
Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Child, Preschool; Electrocardiography, Ambulatory; Fema | 2020 |
Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.
Topics: Academic Medical Centers; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Boston; Drug Dosage Cal | 2020 |
Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study.
Topics: Aged; Anti-Arrhythmia Agents; Asian People; Atrial Fibrillation; Atrial Flutter; Cause of Death; Dro | 2020 |
Diurnal QT analysis in patients with sotalol after cardioversion of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electrocardiography; Humans; Sot | 2021 |
Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; | 2021 |
Outpatient Initiation of Sotalol in Patients with Atrial Fibrillation: Utility of Cardiac Implantable Electronic Devices for Therapy Monitoring.
Topics: Atrial Fibrillation; Defibrillators, Implantable; Humans; Monitoring, Physiologic; Outpatients; Sota | 2021 |
Atrial fibrillation management in a breeding stallion.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Breeding; Electric Countershock; Horse Disease | 2017 |
Trends in outpatient anti-arrhythmic prescriptions for atrial fibrillation and left atrial ablation in Australia: 1997-2016.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrilla | 2018 |
Effect of sotalol on heart rate, QT interval, and atrial fibrillation cycle length in horses with atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Echocardiography, Dopple | 2018 |
Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Stud | 2018 |
Associations between relevant cardiovascular pharmacotherapies and incident heart failure in patients with atrial fibrillation: a cohort study in primary care.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Calcium Channel Blockers; | 2018 |
Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Dronedarone; Female; Flecainide; | 2018 |
Case 9-2019: A 62-Year-Old Man with Atrial Fibrillation, Depression, and Worsening Anxiety.
Topics: Adrenergic beta-Antagonists; Alcohol Drinking; Antidepressive Agents; Anxiety Disorders; Aripiprazol | 2019 |
Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
Topics: Acetanilides; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 2013 |
Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Early Diagnosis; Exercise; Female; Flecainide; H | 2013 |
Comparative effectiveness of pharmacotherapies for prevention of atrial fibrillation following coronary artery bypass surgery.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fib | 2013 |
Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Dis | 2014 |
Electrocardiographic markers of repolarization heterogeneity during dofetilide or sotalol initiation for paroxysmal atrial fibrillation.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Diagnosis, Computer- | 2014 |
ECG response: September 23, 2014.
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Drug Therapy, Combination; Electr | 2014 |
Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cost-Benefit Analysis; Disease-Free Surviva | 2015 |
Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Droned | 2014 |
Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Databases, Factual; Droneda | 2015 |
Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Drug-Related Side Effects and Adverse Reac | 2015 |
Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; | 2016 |
ECG of the Month. Persistent atrial tachycardia after cardioversion in a horse.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electrocardiography; Ho | 2015 |
[A change in adrenal responsiveness in sotalol-treated patients with paroxysmal atrial fibrillation depending on autonomic nervous system tone].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Autonomic Nervous System; Coronary Disease; | 2016 |
Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits.
Topics: Amiodarone; Animals; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Remodeling; Bepri | 2016 |
Mortality risk of sotalol and amiodarone for post-CABG atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Canada; Comorbidity; Coronary Artery Bypas | 2016 |
The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Prescriptions; Drug Utili | 2016 |
Impact of QT interval prolongation following antiarrhythmic drug therapy on left ventricular function.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electrocardiography | 2017 |
Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children.
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Dr | 2017 |
Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease.
Topics: Administration, Oral; Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Natriur | 2008 |
Effects of intrapericardial sotalol and flecainide on transmural atrial electrophysiology and atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Stimulation; Electrocardiography; Ele | 2009 |
Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents; Atrial Fibrillation; Ciprofloxacin; | 2009 |
Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Health Care Costs; Hospitalization; Human | 2009 |
Sotalol and a broken heart.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Long QT Syndrome; So | 2010 |
[Effectiveness of D,L-sotalol in post-ablative atrial arrhythmias in patients with atrial fibrillation treated with radiofrequency ablation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Catheter | 2009 |
d,l-Sotalol reverses abbreviated atrial refractoriness and prevents promotion of atrial fibrillation in a canine model with left ventricular dysfunction induced by atrial tachypacing.
Topics: Action Potentials; Administration, Oral; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agent | 2009 |
Reversible vestibular dysfunction secondary to sotalol use.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Middle Aged; Sotalol; Vestibular Diseases | 2010 |
[79-year-old patient with paroxysmal artial fibrillation and syncope].
Topics: Aged; Antihypertensive Agents; Atrial Fibrillation; Diagnosis, Differential; Electrocardiography; Hu | 2009 |
Atrial fibrillation degenerates into ventricular fibrillation.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Defibrillators, Impla | 2010 |
Rhythm control agents and adverse events in patients with atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Female; | 2010 |
[Atrial fibrillation in patients with type 2 diabetes mellitus: specific features of development and antirecurrence therapy].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Atrial Fi | 2010 |
Augmenting maintenance of sinus rhythm in the control of atrial fibrillation by antiarrhythmic drug combinations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Drug Therap | 2010 |
Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Evidence-Based Medicine; Fleca | 2011 |
Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Dr | 2011 |
Combined blockade of early and late activated atrial potassium currents suppresses atrial fibrillation in a pig model of obstructive apnea.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Male; Models, Animal; Potassium; P | 2011 |
Pharmacological treatment of atrial fibrillation: what does it take?
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Male; Potassium Channels, Voltage- | 2011 |
Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.
Topics: Acetanilides; Action Potentials; Adrenergic beta-Agonists; Animals; Anisoles; Anti-Arrhythmia Agents | 2012 |
Comparative pharmacophysiology of vernakalant, ranolazine, and d-sotalol in canine pulmonary vein sleeve preparations: new flavors or same old taste?
Topics: Acetanilides; Animals; Anisoles; Atrial Fibrillation; Humans; Piperazines; Pulmonary Veins; Pyrrolid | 2012 |
One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Ma | 2011 |
[Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Comorbidity; Diabete | 2013 |
Estimation and prediction of drug therapy on the termination of atrial fibrillation by autoregressive model with exogenous inputs.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Computer Simulation; Female; Heart Conduction | 2013 |
Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness.
Topics: Acetanilides; Administration, Oral; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Fl | 2013 |
Electrophysiologic actions of dl-sotalol in patients with persistent atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; Elec | 2002 |
Findings suggest revised atrial fibrillation approach.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channe | 2003 |
A case series of sotalol-induced torsade de pointes in patients with atrial fibrillation--a tale with a twist.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Middle Aged; Sotalol; Torsades de | 2003 |
Impact of left atrial size reduction on chronic atrial fibrillation in mitral valve surgery.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pac | 2003 |
Clinical predictors and time course of arrhythmia recurrence in patients with early reinitiation of atrial fibrillation after successful internal cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Electric Countershock; Fema | 2003 |
New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Databases, Factual; Drug Prescriptions; | 2003 |
Initiation and monitoring of class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Administration Schedule; Drug Approval; Drug Label | 2003 |
[Correction of rate and structure of ventricular rhythm in permanent atrial fibrillation: a novel pathogenetic approach].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Digoxin; Electrocardi | 2004 |
Atrial fibrillation: rate control often better than rhythm control.
Topics: Adult; Aged; Amiodarone; Anticoagulants; Arrhythmia, Sinus; Atrial Fibrillation; Canada; Disopyramid | 2004 |
[Treatment of atrial fibrillation in a Hungarian hospital department of cardiologic internal medicine at the turn of the millennium].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrill | 2004 |
[Perspectives and limitations in the treatment of vagus-induced atrial fibrillation. Insights from cellular pharmacology].
Topics: Adult; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cells, Cultured; Culture Media; Heart A | 2004 |
Is atrial remodeling a viable target for prevention of atrial fibrillation recurrence?
Topics: Action Potentials; Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2004 |
Limitations to antiarrhythmic drug use in patients with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Contraindications; Female; Fl | 2004 |
[PAFAC Study. Secondary prevention of atrial fibrillation after cardioversion].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therap | 2005 |
Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Electric Countershock; Electr | 2005 |
Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Middle Aged; Recu | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Quality of Life; Sotalol | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Hum | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Sex Factors; Sotalol; | 2005 |
Ablation of atrial fibrillation using microwave energy--early experience.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Coronary Ar | 2005 |
Proarrhythmias and antiarrhythmias: two sides of the same coin.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2005 |
Potential proarrhythmic effect of biventricular pacing: fact or myth?
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2005 |
Sotalol and amiodarone versus digoxin for conversion of recent onset atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Humans; Sotalol; Time Factors | 2005 |
Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Electric Countershock; Fema | 2006 |
Inadvertent toxic drug reaction in the management of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Digoxin; Drug Interactions; Electrocardiog | 2006 |
[Conversion in sinus rhythm].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; Dose-Response Relationship, Dr | 2006 |
[Conversion to sinus rhythm].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Diagnosis, Differential; Diarrhea; Electri | 2006 |
Does prophylactic sotalol and magnesium decrease the incidence of atrial fibrillation following coronary artery bypass surgery: a propensity-matched analysis.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemoprevention; Coronary A | 2006 |
Combined use of 1C and III agents for highly symptomatic, refractory atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Drug Combinations; Female | 2006 |
Comparison of a standard versus accelerated dosing regimen for D,L-sotalol for the treatment of atrial and ventricular dysrhythmias.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; California; Dose-Response R | 2006 |
Fetal atrial flutter: a case report and experience of sotalol treatment.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Delivery, | 2006 |
Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atr | 2008 |
Sotalol-induced delayed ventricular repolarization in man.
Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrophysiology; Heart; Hear | 1980 |
[Embolic episodes after treatment of atrial fibrillation in a patient with thyrotoxicosis].
Topics: Anticoagulants; Arterial Occlusive Diseases; Atrial Fibrillation; Embolectomy; Embolism; Humans; Mal | 1995 |
Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms.
Topics: Acetylcholine; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutt | 1995 |
Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.
Topics: Aminobenzoates; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Bridged Bicyc | 1994 |
Sotalol and end-stage renal failure.
Topics: Aged; Atrial Fibrillation; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Sotalol | 1994 |
Undersensing during ventricular tachyarrhythmias in a third-generation implantable cardioverter defibrillator: diagnosis using stored electrograms and correction with programming.
Topics: Aged; Atrial Fibrillation; Defibrillators, Implantable; Electrocardiography; Electrophysiology; Equi | 1994 |
Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Dilated; Drug Combinati | 1994 |
Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
Topics: Animals; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; Dogs; Electric Stimulatio | 1993 |
Effect of low dose sotalol on the signal averaged P wave in patients with paroxysmal atrial fibrillation.
Topics: Adult; Aged; Algorithms; Anti-Arrhythmia Agents; Atrial Fibrillation; Computers; Cross-Over Studies; | 1995 |
Effect of parenteral d-sotalol on transvenous atrial defibrillation threshold in a canine model of atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Coronary Vessels; Defib | 1996 |
Sotalol proarrhythmia: a report of five cases and an audit of the use of a sotalol in a teaching hospital.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hospitals, Teac | 1996 |
Torsades de pointes from terfenadine and sotalol given in combination.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Interactions; Electrocardiography; Female; H | 1996 |
Low energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing | 1997 |
Initial clinical experience with an implantable human atrial defibrillator.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Arti | 1997 |
Sotalol for atrial tachycardias after surgery for congenital heart disease.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bradycardi | 1997 |
[The effect of sotalol hydrochloride therapy on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Electrocardi | 1996 |
Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershoc | 1997 |
[Biatrial stimulation in therapy of paroxysmal atrial tachycardia: a case report].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function; Combined Modalit | 1997 |
A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold.
Topics: Acute Disease; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Combined Modality Thera | 1997 |
Leukocytoclastic vasculitis associated with sotalol therapy.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Exanthema; Humans; Male; Skin Diseases, Vascular; | 1998 |
Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Electric Countershock; Female; Fol | 1998 |
[Noninvasive monitoring of anti-arrhythmia sotalol therapy by analysis of intracardiac signals].
Topics: Aged; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Dogs; Electrocardiograph | 1997 |
Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia | 1998 |
[Sotalol--atrial fibrillation, reduced renal function and sudden death].
Topics: Acute Kidney Injury; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Death, Sudden, Cardiac; | 1998 |
T wave alternans after sotalol: evidence for increased sensitivity to sotalol after conversion from atrial fibrillation to sinus rhythm.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Female; | 1998 |
Long-term outcome in patients with chronic atrial fibrillation after successful internal cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Countershoc | 1999 |
Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Disease Models, Animal; Elect | 1999 |
Redefining the role of antiarrhythmic drugs.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Chemotherapy, Adjuvant; Defibrillators, Implantable; El | 1999 |
Prevention of postoperative atrial fibrillation: what is the best approach?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Humans; Sotalol | 1999 |
Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrilla | 1999 |
Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Electric Countershock | 1999 |
Cardioversion with sotalol in selected patients with vagally and adrenergically mediated paroxysmal atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Adrenergic Fibers; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrilla | 1999 |
Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: assessment of the electrophysiological effects by biatrial basket electrodes.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Thera | 2000 |
[Ion channels and arrhythmias].
Topics: Action Potentials; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atrial Fib | 2000 |
[Paroxysmal atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electric Countershock; F | 2000 |
Sotalol in the treatment of fetal dysrhythmias.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Hydrops Fetalis; Inf | 2000 |
Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; Humans; Hypertrophy, Left | 2000 |
Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation.
Topics: Acetylcholine; Action Potentials; Adenosine; Adrenergic beta-Antagonists; Animals; Arrhythmias, Card | 2000 |
Oral d,l-sotalol in atrial fibrillation and/or flutter.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation | 2000 |
Frequency-dependent electrophysiological effects of flecainide, nifekalant and d,l-sotalol on the human atrium.
Topics: Action Potentials; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Func | 2001 |
The frequency analysis of signal-averaged ECG of P wave as predictor of efficacy of class III antiarrhythmic drugs to maintain sinus rhythm in recurrent idiopathic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; | 2001 |
The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Premature Complexes; Dogs; Drug Adminis | 2001 |
Comparison of class III antiarrhythmic drugs versus digoxin for the reversion of new-onset atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Humans; Sotalol; Time Factors; Tre | 2001 |
Oral amiodarone and atrial fibrillation.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibril | 2001 |
Sotalol: a fool's deal?
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cohort Studies; Humans; Sotalol | 2001 |
Effects of oral sotalol administration before electrical cardioversion of persistent atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Ma | 2001 |
Global distribution of atrial ectopic foci triggering recurrence of atrial tachyarrhythmia after electrical cardioversion of long-standing atrial fibrillation: a bi-atrial basket mapping study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; | 2001 |
[Chronic hepatitis ascribed to the use of sotalol].
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Chemical and | 2001 |
[Atrial fibrillation successfully converted. A new standard in the prevention of recurrence?].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Calcium Ch | 2001 |
Maintainance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Electric Countershock; Humans; Sotalol | 2002 |
Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electro | 2002 |
Suppression of atrial fibrillation by multisite and septal pacing in a novel experimental model.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Atrial Fibrillation; Cardiac Pacing, Art | 2002 |
Amiodarone: pearl or peril?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Propafenone; | 2002 |
Atrial fibrillation in Wolff-Parkinson-White syndrome: reversal of isoproterenol effects by sotalol.
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrocardiography; Female; Heart Conductio | 1992 |
Sotalol-induced torsade de pointes: management with magnesium infusion.
Topics: Aged; Amiodarone; Atrial Fibrillation; Dose-Response Relationship, Drug; Electrocardiography, Ambula | 1992 |
Treatment of atrial fibrillation: time for change?
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Digitalis Glycosides; Digoxin; Humans; | 1992 |
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
Topics: Actuarial Analysis; Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Chr | 1991 |
Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Data Interpretation, Statistical; Drug Administrat | 1990 |
New hope in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Quinidine; Sotalol | 1990 |
Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; | 1989 |
Sudden death in hemochromatosis after closed-chest catheter ablation of the atrioventricular junction.
Topics: Atrial Fibrillation; Atrioventricular Node; Death, Sudden; Electric Countershock; Electrocardiograph | 1988 |
Differential effect of some antiarrhythmic drugs in right- or left-sided aconitine-induced experimental atrial arrhythmias.
Topics: Aconitine; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dogs; Female; Male; | 1987 |
Successful termination of combined rapid atrial flutter/fibrillation and ventricular tachycardia by intravenous sotalol.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Humans; Infusions | 1987 |
Protection against ventricular and atrial fibrillation by sotalol.
Topics: Action Potentials; Animals; Atrial Fibrillation; Cardiopulmonary Bypass; Dogs; Heart; Sotalol; Ventr | 1986 |
[Effects of oral sotalol on the conduction of accessory atrioventricular pathways].
Topics: Administration, Oral; Adult; Atrial Fibrillation; Electrocardiography; Female; Heart Conduction Syst | 1985 |
Sotalol infusion in the treatment of supraventricular tachyarrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Female; Humans; Male; Middle | 1985 |
Effect of Sotalol on clinical arrhythmias.
Topics: Administration, Oral; Aged; Amino Alcohols; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutte | 1972 |